Original Article
A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
N Engl J Med 2005; 352:2271-2284June 2, 2005DOI: 10.1056/NEJMoa051016
- Abstract
Background
The incidence and severity of herpes zoster and postherpetic neuralgia increase with age in association with a progressive decline in cell-mediated immunity to varicella–zoster virus (VZV). We tested the hypothesis that vaccination against VZV would decrease the incidence, severity, or both of herpes zoster and postherpetic neuralgia among older adults.
Methods
We enrolled 38,546 adults 60 years of age or older in a randomized, double-blind, placebo-controlled trial of an investigational live attenuated Oka/Merck VZV vaccine (“zoster vaccine”). Herpes zoster was diagnosed according to clinical and laboratory criteria. The pain and discomfort associated with herpes zoster were measured repeatedly for six months. The primary end point was the burden of illness due to herpes zoster, a measure affected by the incidence, severity, and duration of the associated pain and discomfort. The secondary end point was the incidence of postherpetic neuralgia.
Results
More than 95 percent of the subjects continued in the study to its completion, with a median of 3.12 years of surveillance for herpes zoster. A total of 957 confirmed cases of herpes zoster (315 among vaccine recipients and 642 among placebo recipients) and 107 cases of postherpetic neuralgia (27 among vaccine recipients and 80 among placebo recipients) were included in the efficacy analysis. The use of the zoster vaccine reduced the burden of illness due to herpes zoster by 61.1 percent (P<0.001), reduced the incidence of postherpetic neuralgia by 66.5 percent (P<0.001), and reduced the incidence of herpes zoster by 51.3 percent (P<0.001). Reactions at the injection site were more frequent among vaccine recipients but were generally mild.
Conclusions
The zoster vaccine markedly reduced morbidity from herpes zoster and postherpetic neuralgia among older adults.
Media in This Article
Figure 1
Diagram of the Study Design and Results.Figure 2
Kaplan–Meier Estimates of the Effect of Zoster Vaccine on the Cumulative Incidence of Postherpetic Neuralgia (Panel A) and Herpes Zoster (Panel B) in the Modified Intention-to-Treat Population.Article Activity
- Article
Herpes zoster, or shingles, is characterized by unilateral radicular pain and a vesicular rash that is generally limited to a single dermatome.1,2 Herpes zoster results from reactivation of latent varicella–zoster virus (VZV) within the sensory ganglia.3,4 The incidence and severity of herpes zoster increase with advancing age; more than half of all persons in whom herpes zoster develops are older than 60 years. Complications occur in almost 50 percent of older persons with herpes zoster.3-5 The most frequent debilitating complication is postherpetic neuralgia, a neuropathic pain syndrome that persists or develops after the dermatomal rash has healed.5-9 The frequency and severity of postherpetic neuralgia also increase with increasing age.9-11 The pain and discomfort associated with herpes zoster can be prolonged and disabling, diminishing the patient's quality of life and ability to function to a degree comparable to that in diseases such as congestive heart failure, myocardial infarction, diabetes mellitus type 2, and major depression.12 Antiviral therapy reduces the severity and duration of herpes zoster but does not prevent the development of postherpetic neuralgia.2,11 Postherpetic neuralgia may persist for years and is often refractory to treatment.13
Forty years ago, Hope-Simpson proposed that immunity to VZV plays a pivotal role in the pathogenesis of herpes zoster,3 and subsequent observations support the thesis that cell-mediated immunity to VZV is a major determinant of the risk and severity of herpes zoster.3,7,11,14-17 Whereas levels of antibody to VZV remain relatively constant with increasing age, the increased incidence and severity of herpes zoster and postherpetic neuralgia among older adults are closely linked to a progressive age-related decline in cell-mediated immunity to VZV.4-8,14-21 Recurrences of herpes zoster are uncommon among immunocompetent persons, presumably because an episode of herpes zoster boosts immunity to VZV, effectively “immunizing” against a subsequent episode.3,4,7,8,22
Previous studies have shown that VZV vaccines can elicit a significant increase in cell-mediated immunity to VZV in immunocompetent older adults21-25 and reduce the incidence and severity of herpes zoster in recipients of bone marrow allografts.26,27 These observations led us to hypothesize that immunization of older persons with a VZV vaccine would boost their cell-mediated immunity to VZV and thereby provide protection against herpes zoster and postherpetic neuralgia.22 The Shingles Prevention Study (Department of Veterans Affairs [VA] Cooperative Study No. 403) was conducted to determine whether vaccination with a live attenuated VZV vaccine would decrease the incidence, severity, or both of herpes zoster and postherpetic neuralgia in adults 60 years of age or older.
Methods
A detailed description of the methods used in this study is provided in the Supplementary Appendix (available with the full text of this article at www.nejm.org). A brief overview is presented here.
Study Design
We conducted a randomized, placebo-controlled, double-blind clinical trial at 22 sites, in which adults 60 years of age or older received either VZV vaccine or placebo. The study was approved by a human rights committee of the VA Cooperative Studies Program (VACSP) and by the local institutional review boards at all study sites. An independent data and safety monitoring board reviewed the safety data and the interim results.
Study Population
Eligible subjects had a history of varicella or had resided in the continental United States for at least 30 years. Immunocompromised persons and those unable to adhere to the study protocol were excluded. All subjects provided written informed consent.
Intervention
Subjects received one subcutaneous injection of 0.5 ml of the investigational live attenuated Oka/Merck VZV vaccine (“zoster vaccine”) or placebo. The estimated potency at vaccination of the 12 vaccine lots used in the study ranged from 18,700 to 60,000 plaque-forming units per dose. The median potency was 24,600 plaque-forming units, and more than 90 percent of vaccinated subjects received 32,300 plaque-forming units or less.
Follow-up
Active follow-up and ascertainment of cases of herpes zoster were ensured by an interactive automated telephone-response system, which subjects called monthly. If a subject's responses to a standardized set of questions suggested a possible case of herpes zoster, the subject was instructed to contact the local study site immediately, and a fax containing the subject's response was sent to the site. Subjects who did not call the automated telephone-response system within a pre-established length of time were called by the automated telephone-response system. If this effort to reach the subject failed, the local study site was notified by fax to contact the subject directly. At the end of the study, subjects were asked to report any previously unreported episodes of herpes zoster.
Safety Evaluation
All adverse events occurring within 42 days after vaccination were recorded. Thereafter, only serious adverse events were recorded if reported by the subject and considered by the study physician to be related to the vaccination. Deaths were identified on the basis of reports from family members and during follow-up of missed monthly calls to the automated telephone-response system.
Approximately 300 subjects at each of the study sites were enrolled in a substudy that more closely monitored adverse events. These subjects maintained a daily log of body temperature and a “report card” of symptoms related to the injection site and other clinical symptoms during the 42 days after vaccination. Thereafter, they were followed to identify all hospitalizations.
Identification and Evaluation of Suspected Cases of Herpes Zoster
At enrollment, the subjects were educated with regard to the signs and symptoms of herpes zoster. Those who had a new rash or new unilateral pain were urged to contact their study site immediately. Study personnel attempted to evaluate all subjects with new rashes as soon as possible. Subjects with unilateral rashes and no alternative clinical diagnoses were classified as having “suspected cases of herpes zoster” and were followed according to the study protocol. The evaluating physician offered subjects with clinically diagnosed herpes zoster, without cost, the licensed antiviral drug famciclovir (Famvir, SmithKline Beecham and Novartis Pharmaceuticals), in accordance with the manufacturer's recommendations, and with standard-of-care treatment for pain. Pain management was not specified by the study protocol.
Herpes zoster–associated pain (including unpleasant sensations such as allodynia and pruritus, which are not always characterized as pain by persons with herpes zoster) was measured with the use of the Zoster Brief Pain Inventory, an assessment tool in the form of a questionnaire completed by the subject that was specifically designed to measure pain and discomfort in herpes zoster.28 This questionnaire and others29,30 were used to assess the effect of herpes zoster on the subjects' activities of daily living, quality of life, and general health status. Characteristics of the rash, associated complications, and medication use were also recorded. Evaluations based on responses to the questionnaires were repeated over a period of at least 182 days, according to a schedule specified by the study protocol. Digital photographs and specimens for laboratory diagnosis were obtained from subjects with suspected cases of herpes zoster.
Confirmation of Cases
Before unblinding, each suspected case of herpes zoster was classified as a confirmed case of herpes zoster or as not a confirmed case with the use of a hierarchical algorithm that incorporated the results of the polymerase-chain-reaction (PCR) assay performed at the central laboratory of the study, virus culture at the local virology laboratory, and the final clinical diagnosis of the study's clinical evaluation committee, consisting of five physicians with expertise in herpes zoster.
The PCR assay, designed to detect and discriminate among DNA from wild-type and vaccine strains of VZV and from herpes simplex virus (HSV), could detect approximately 13 copies of DNA from wild-type or the vaccine strain of VZV. The PCR assays included primers and a probe for the human beta-globin gene to verify the presence of cellular DNA in the specimens from the lesions.
If the PCR assay revealed VZV DNA, the suspected case of herpes zoster was classified as a confirmed case; if the assay was positive for beta-globin or HSV DNA and negative for VZV DNA, the case was classified as not a case of herpes zoster. If the specimen obtained for the assay was inadequate (i.e., was negative for both viral and beta-globin DNA) or was missing, the final diagnosis was determined by the isolation of VZV or HSV in the local virology laboratory. In the absence of a valid laboratory diagnosis, the case was classified on the basis of the clinical diagnosis by the clinical evaluation committee.
Efficacy End Points
The primary end point was the burden of illness due to herpes zoster, a severity-by-duration measure of the total pain and discomfort associated with herpes zoster in the population of study subjects.28,31,32 For each confirmed case of herpes zoster, responses to the “worst pain” question in the Zoster Brief Pain Inventory were used to calculate a herpes-zoster severity-of-illness score, defined as the area under the curve (AUC) of herpes-zoster pain plotted against time during the 182-day period after the onset of rash. Subjects in whom herpes zoster developed had severity-of-illness scores ranging from 0 to 1813. Increasing mean scores are highly correlated with a decrease in the health-related quality of life and in functional status among older adults.28,33 A score of 0 was recorded for subjects in whom herpes zoster did not develop during the study period.
The “herpes-zoster burden-of-illness score” represented the average severity of illness among all subjects in the vaccine or placebo groups; it was calculated as the sum of the herpes-zoster severity-of-illness scores of all members of a group divided by the total number of subjects in the group. The secondary end point was the incidence of postherpetic neuralgia, defined as pain associated with herpes zoster that was rated as 3 or more on a scale ranging from 0 (“no pain”) to 10 (“pain as bad as you can imagine”), persisting or appearing more than 90 days after the onset of rash. Scores lower than 3 were not associated with significant decrements in the quality of life or the ability to carry out activities of daily living and were therefore not considered to represent postherpetic neuralgia.10,28
Statistical Analysis
A data-analysis plan was completed before the data were unblinded for analysis.31,34-38 The analysis was performed by the VACSP coordinating center (West Haven, Conn.), with review and approval by the executive committee of the study. Vaccine efficacy with respect to the burden of illness due to herpes zoster (VEBOI) was defined as the relative reduction in the burden-of-illness score in the vaccine group as compared with that in the placebo group and calculated as 1 – relative risk (i.e., 1 – the herpes-zoster burden-of-illness score in the vaccine group divided by the herpes-zoster burden-of-illness score in the placebo group). The prespecified criteria for the success of the vaccine with respect to the burden of illness due to herpes zoster required a VEBOI point estimate of 47 percent or more and a lower bound of the 95 percent confidence interval greater than 25 percent. A method of assessing the combined effect of disease incidence, severity, and duration, weighted for age group, was used.31
Vaccine efficacy with respect to the incidence of postherpetic neuralgia (VEPHN) was defined as the relative reduction in the incidence of postherpetic neuralgia in the vaccine group as compared with that in the placebo group. The prespecified criteria for the success of the vaccine with respect to the incidence of postherpetic neuralgia required a VEPHN point estimate of 62 percent or more and a lower bound of the 95 percent confidence interval greater than 25 percent. The VEPHN was calculated with the use of a conditional exact method weighted for age group.34-36 The VEPHN was also calculated with the use of alternative definitions of postherpetic neuralgia as pain present for more than 30, 60, 120, and 182 days after the onset of rash caused by herpes zoster. Vaccine efficacy with respect to the incidence of herpes zoster (VEHZ) was calculated similarly.
Efficacy analyses were performed with the use of a follow-up period that excluded the first 30 days after vaccination and excluded subjects who withdrew and those in whom a confirmed case of herpes zoster developed within the first 30 days after vaccination. The results were essentially unchanged when subjects in whom herpes zoster developed during the first 30 days were included. All reported P values are two-sided.
Conduct of the Study
The study was designed by the planning and executive committees of the Shingles Prevention Study Group, the members of which were selected for relevant expertise, with the support of a planning grant from the VACSP to the study chairs (details are provided in the Supplementary Appendix). Merck contributed to the planning process through two nonvoting members on these committees. The statistical methods for analyzing burden of illness were developed and published by Merck statisticians before the initiation of the study.31 The study was initiated and implemented as a VA Cooperative Study in collaboration with the National Institute of Allergy and Infectious Diseases and Merck. Merck, the holder of the investigational new drug application, participated in the organization of oversight activities and monitored the progress of the study. The Covalent Group, an independent company, was hired by Merck to monitor case report forms and adherence to the study protocol and to report to Merck and the VACSP. The participating investigators and their staff gathered the data. An unblinded statistician at the VACSP coordinating center, who was not involved in the operation of the study, presented unblinded safety data to the data and safety monitoring board.
Management and consolidation of the data were performed by the VACSP coordinating center. Data-analysis programs were developed and tested by biostatisticians and programmers at the coordinating center and at Merck. The data were analyzed at the coordinating center. The executive committee reviewed and approved the data-analysis plan and all analyses of vaccine efficacy and safety and vouches for the study's results. The writing committee, all members of which were also members of the executive committee, wrote the manuscript and takes responsibility for it.
Results
Characteristics of the Study Subjects
A total of 38,546 subjects were enrolled in the study between November 1998 and September 2001 (Figure 1Figure 1
Diagram of the Study Design and Results.). The numbers enrolled at each study site ranged from 1167 to 2508. Follow-up was completed in April 2004. The demographic characteristics of the two study groups were similar (Table 1Table 1
Baseline Characteristics of the Study Participants.). The median age in both groups was 69 years; 6.6 percent of the vaccine recipients and 6.9 percent of the placebo recipients were 80 years of age or older. At enrollment, most of the subjects had no health-related limitations on their activities (51.3 percent) or mild health-related limitations (38.6 percent). More than 95 percent of the subjects were actively followed to the end of the study (Figure 1) and completed a closeout interview. The mean duration of herpes zoster surveillance was 3.13 years (median, 3.12 years; range, 1 day to 4.90 years) with no difference in duration between the groups. Only 0.6 percent of the subjects withdrew from the study or were lost to follow-up; 4.1 percent died during the study.Confirmed Cases for the Efficacy Analyses
More than 3500 rashes that developed in subjects in each treatment group were evaluated clinically but were not considered to be suspected cases of herpes zoster. A total of 1308 subjects with suspected herpes zoster were evaluated according to the protocol (Figure 1). Among these subjects, 317 (156 in the vaccine group and 161 in the placebo group) were determined not to have herpes zoster. Of these 317 subjects, 49 had rashes that were caused by HSV (24 in the vaccine group and 25 in the placebo group). Closeout interviews did not identify any previously unreported cases of herpes zoster. Of the 1308 suspected cases of herpes zoster, the final diagnosis in 1156 cases (88.4 percent; 417 in the vaccine group and 739 in the placebo group) was based on the results of the PCR assay.
Of the 1308 suspected cases, 984 (75.2 percent) were determined to be confirmed cases. In accordance with the protocol, 24 cases were excluded from the efficacy analyses because they occurred within 30 days of vaccination (6 in the vaccine group and 18 in the placebo group) and 3 because they were a subject's second episode of herpes zoster (Figure 1). The remaining 957 confirmed cases of herpes zoster (315 in the vaccine group and 642 in the placebo group) constituted the end points of the efficacy analyses. The results of PCR testing were positive for wild-type VZV DNA in more than 93 percent of the confirmed cases of herpes zoster in each study group (Figure 1). Vaccine virus DNA was not detected in any subjects with suspected herpes zoster.
The rate of use of antiviral medication among subjects with confirmed cases of herpes zoster was similar in the two groups (87.3 percent in the vaccine group and 85.7 percent in the placebo group), as was the proportion in whom treatment was initiated within 72 hours of the onset of rash — in 64.1 percent in the vaccine group and 65.9 percent in the placebo group. The frequency of use of various medications to treat pain resulting from herpes zoster was similar in the two groups, and the average duration of the use of opioids and the average quantity of opioids used among subjects with herpes zoster were greater in the placebo group than in the vaccine group. Thus, differences in the use of pain medication did not inflate the estimates of VEBOI or VEPHN.
Burden of Illness Due to Herpes Zoster
The herpes-zoster burden-of-illness score was significantly reduced in the vaccine group as compared with the placebo group (P<0.001) (Table 2Table 2
Effect of Zoster Vaccine on the Burden of Illness in Herpes Zoster in the Modified Intention-to-Treat Population.). Overall, VEBOI was 61.1 percent (95 percent confidence interval, 51.1 to 69.1), a result that met the prespecified criteria for success. There were no significant differences in the VEBOI when the results were stratified according to sex or age (Table 2).Incidence of Postherpetic Neuralgia
There were 107 cases of postherpetic neuralgia, 27 in the vaccine group and 80 in the placebo group (0.46 case vs. 1.38 cases per 1000 person-years, respectively; P<0.001) (Table 3Table 3
Effect of Zoster Vaccine on the Incidence of Postherpetic Neuralgia in the Modified Intention-to-Treat Population.). Overall, the VEPHN was 66.5 percent (95 percent confidence interval, 47.5 to 79.2), a result that met the prespecified criteria for success. There were no significant differences in the VEPHN when the results were stratified according to sex or age (Table 3).The VEPHN did not change appreciably when postherpetic neuralgia was defined with the use of alternative cutoff times for the duration (persistence) of pain (Table 3). In a time-to-event analysis, the cumulative incidence of postherpetic neuralgia was significantly lower in the vaccine group than in the placebo group (P<0.001) (Figure 2AFigure 2
Kaplan–Meier Estimates of the Effect of Zoster Vaccine on the Cumulative Incidence of Postherpetic Neuralgia (Panel A) and Herpes Zoster (Panel B) in the Modified Intention-to-Treat Population.).Incidence of Herpes Zoster
The overall incidence of herpes zoster per 1000 person-years was significantly reduced by the zoster vaccine, from 11.12 per 1000 person-years in the placebo group to 5.42 per 1000 person-years in the vaccine group (P<0.001) (Table 2). The VEHZ was 51.3 percent (95 percent confidence interval, 44.2 to 57.6). In a time-to-event analysis, the cumulative incidence of herpes zoster was significantly lower in the vaccine group than in the placebo group (P<0.001) (Figure 2B). The VEHZ was 37.6 percent among subjects 70 years of age or older and 63.9 percent among younger subjects (P<0.001). There was no difference in VEHZ according to sex.
Duration and Severity of Herpes Zoster
The median duration of pain and discomfort among subjects with confirmed cases of herpes zoster was significantly shorter in the vaccine group than in the placebo group (21 days vs. 24 days, P=0.03). Similarly, the mean herpes-zoster severity-of-illness score (AUC) among subjects with confirmed cases of herpes zoster was significantly lower in the vaccine group than in the placebo group (141.2 vs. 180.5, P=0.008). For almost every level of the severity-of-illness score, there were fewer cases of herpes zoster in the vaccine group than in the placebo group. The effect of the zoster vaccine on the severity of illness was greater among older subjects; thus, the VEBOI, the primary end point of the study, was maintained at 55.4 percent.
Vaccine Safety in the Total Study Population
Over the entire study period, the numbers and percentages of deaths were similar in both study groups (Table 4Table 4
Adverse Events among All Subjects and among Those in the Adverse-Events Substudy.). During the first 42 days after vaccination, the number and types of serious adverse events were similar in the two groups (Table 4), as was the distribution of serious adverse events according to body system (data not shown). During this period, varicella-like rashes at the injection site occurred more frequently among those in the vaccine group than among those in the placebo group, but varicella-like rashes at other sites occurred at similar rates in the two groups (Table 4). There were 7 confirmed cases of herpes zoster in the vaccine group and 24 in the placebo group during the first 42 days after vaccination.Five subjects had serious adverse events that were assessed by site investigators as possibly vaccine-related. Two subjects had received vaccine: a 64-year-old woman who had an exacerbation of asthma two days after receiving the vaccination, and an 80-year-old man in whom symptoms of polymyalgia rheumatica developed on day 3. The remaining three subjects, all men, who had serious adverse events had received placebo: the first subject was 65 years of age and had an anaphylactoid reaction 90 minutes after receiving the vaccination (and 30 minutes after eating peanuts); the second was 69 years of age and received a diagnosis of polymyalgia rheumatica on day 15; and the third was 78 years of age and received a diagnosis of Goodpasture's syndrome on day 52.
Adverse-Events Substudy
In the adverse-events substudy, a significantly greater number of subjects in the vaccine group had one or more adverse events than in the placebo group, reflecting a greater frequency of adverse events at the injection site among subjects in the vaccine group (Table 4). In the vaccine group, the most frequent adverse events at the injection site were erythema (in 35.8 percent of the vaccine group), pain or tenderness (in 34.5 percent), swelling (in 26.2 percent), and pruritus (in 7.1 percent). No other adverse event at the injection site was observed in more than 2 percent of the vaccine recipients. Overall, the proportion of subjects with one or more systemic adverse events was similar in the two groups; however, systemic adverse events assessed as vaccine-related occurred more frequently among vaccine recipients (Table 4).
In the substudy, during the 42 days after vaccination, significantly more subjects in the vaccine group had serious adverse events than in the placebo group (1.9 percent vs. 1.3 percent, respectively; P=0.03); there were no significant differences in the distribution of serious adverse events according to body system or type of event (data not shown). A post hoc, subject-by-subject review of serious adverse events conducted by the writing committee revealed no clinically meaningful differences between the groups in the pathophysiology, nature, timing, intensity, or outcome of these events.
The number of subjects who had one or more hospitalizations was similar in the two groups. No hospitalization among subjects in either group was considered to be related to the vaccine.
Discussion
The pain and discomfort of herpes zoster and postherpetic neuralgia cause substantial morbidity among older adults.9-12,15,28 Although herpes zoster is not a reportable disease, we estimate that 1 million or more cases occur each year in the United States, a number that is likely to increase as the population ages. Thus, a means of prevention would offer important medical and economic benefits.
The zoster vaccine reduced the burden of illness due to herpes zoster among people 60 years of age or older by 61.1 percent and reduced the incidence of postherpetic neuralgia by 66.5 percent. Significant efficacy with respect to the incidence of postherpetic neuralgia was demonstrated, regardless of how postherpetic neuralgia was defined, with a trend toward greater efficacy for postherpetic neuralgia of longer duration. The vaccine also showed significant efficacy for these end points even when the results were stratified according to age and sex. Zoster vaccine also reduced the overall incidence of herpes zoster by 51.3 percent and significantly reduced the pain and discomfort among subjects in whom herpes zoster developed. Although the effect of zoster vaccine on the incidence of herpes zoster was less among older subjects than among younger subjects, the effect of the vaccine on the severity of illness was greater among older subjects, so that the VEBOI, the primary end point of the study, was maintained at 55.4 percent.
We believe that the observed efficacy of the zoster vaccine reflects its ability to boost immunity to VZV in vaccinated subjects — an issue that will require further study. The investigational zoster vaccine had low rates of serious adverse events, systemic adverse events, hospitalization, and death. Results were similar in the two study groups, and local reactions at the vaccination site were generally mild. The greater number of early cases of herpes zoster in the placebo group, as compared with the vaccine group, and the fact that no vaccine virus DNA was detected, indicate that the vaccine did not cause or induce herpes zoster.
The minimum potency of the zoster vaccine administered to subjects in the study was at least 14 times greater than the minimum potency of Varivax (Merck), the vaccine currently licensed to prevent varicella. A preliminary study indicated that potencies of this magnitude are required to elicit a significant increase in the cell-mediated immunity to VZV among older adults — hence, the need to formulate a high-potency vaccine for this study. We know of no data to suggest that the licensed varicella vaccine would be efficacious in protecting older adults from herpes zoster or postherpetic neuralgia. Thus, we do not recommend the use of the current varicella vaccine in an attempt to protect against herpes zoster and postherpetic neuralgia. The results of our study show that vaccination of immunocompetent persons 60 years of age and older with live attenuated zoster vaccine (Oka/Merck) markedly decreases the morbidity associated with herpes zoster and the incidence of postherpetic neuralgia.
Supported by the Cooperative Studies Program, Department of Veterans Affairs, Office of Research and Development; by a grant from Merck (to the Cooperative Studies Program); and by a grant from the James R. and Jesse V. Scott Fund for Shingles Research (to Dr. Oxman). The vaccine and placebo used for the study were supplied by Merck; famciclovir was supplied by SmithKline Beecham and Novartis Pharmaceuticals.
Drs. Crawford, Gershon, Griffin, Levin, Schmader, and Wright report having received consultation fees, lecture fees, or honoraria from Merck; Drs. Betts, Greenberg, Kauffman, Levin, Weinberg, and Wright report having received grant support from Merck; Drs. Annunziato, C.Y. Chan, I.S.F. Chan, Crawford, Harbecke, Keller, Silber, Simberkoff, and Wang and Ms. Williams report holding equity in Merck; Drs. Annunziato and Levin report having partial interests in relevant patents; and Drs. Annunziato, C.Y. Chan, I.S.F. Chan, Keller, Silber, and Wang are employees of Merck.
This article is dedicated to the memory of the late Edgar Hope-Simpson, whose seminal observations and prescient hypotheses on herpes zoster provided our inspiration and rationale, and to the late John Franklin Enders, who taught us what really matters.
We are indebted to the members of the data safety and monitoring board for ensuring the safety and integrity of the study for a period of six years; to the more than 38,000 subjects whose participation has been the key to the study's success; to Dr. Robert H. Friedman for expert advice regarding the automated telephone-response system; and to Professors Michiaki Takahashi and J. Edwin Seegmiller and the late Richard T. Perkin, founding president of the Varicella–Zoster Virus Research Foundation, for their encouragement.
Source Information
The authors' affiliations are listed in the Appendix.
Address reprint requests to Dr. Oxman at the Shingles Prevention Study (Mail code 111F-1), VA San Diego Healthcare System, 3350 La Jolla Village Dr., San Diego, CA 92161, or at mnoxman@ucsd.edu.
Other members of the Shingles Prevention Study Group are listed in the Appendix.
Appendix
The authors' affiliations are as follows: the Department of Veterans Affairs (VA) San Diego Healthcare System and the Departments of Medicine and Pathology, University of California, San Diego (M.N.O., H.M.W., J.C.G., P.A.B., R.H.); University of Colorado Health Sciences Center, Denver (M.J.L., A.W., A.R.H.); VA Cooperative Studies Program Coordinating Center, West Haven, Conn. (G.R.J., J.H.Z., P.N.P., T.C.K.); Geriatric Research, Education and Clinical Center, Durham VA Medical Center and Center for Aging, and the Department of Medicine, Duke University Medical Center, Durham, N.C. (K.E.S.); Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. (S.E.S., P.B., N.E.S., A.R.M.); St. Louis VA Medical Center and the Department of Medicine, Washington University, St. Louis (L.D.G.); VA Boston Healthcare System, Boston (R.D.A., R.P.G., D.J.C.); VA New York Harbor Healthcare System and the Department of Medicine, New York University School of Medicine, New York (M.S.S.); Columbia University, New York (A.A.G.); New Mexico VA Healthcare System, Albuquerque (L.E.D.); VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque (K.D.B.); National Institute of Allergy and Infectious Diseases, Bethesda, Md. (C.E.B.); Minneapolis VA Medical Center, Minneapolis (V.A.M.); VA Ann Arbor Healthcare System, Ann Arbor, Mich. (C.A.K.); Edward Hines Jr. VA Hospital, Chicago (C.T.P.); VA Puget Sound Healthcare System, Seattle (K.M.N.); University of Rochester Medical Center, Rochester, N.Y. (R.F.B.); Vanderbilt University Medical Center, Nashville (P.F.W., M.R.G.); Baltimore VA Medical Center, Baltimore (S.K.K.); Birmingham VA Medical Center, Birmingham, Ala. (J.W.G.); VA Palo Alto Healthcare System, Palo Alto, Calif. (J.L., M.H.); Baylor College of Medicine, Houston (W.A.K.); University of Texas Health Science Center San Antonio, San Antonio (G.E.C.); Northport VA Medical Center, Northport, N.Y. (S.S.Y., Z.L.); James A. Haley Veterans Hospital, Tampa, Fla. (J.F.T.); Lexington VA Medical Center, Lexington, Ky. (R.N.G.); Merck Research Laboratories, West Point, Pa. (P.M.K., C.Y.C., I.S.F.C., W.W.B.W., P.W.A., J.L.S.); University of California, Los Angeles, Neuropsychiatric Institute, Los Angeles (M.R.I.).
The members of the Shingles Prevention Study Group were as follows: Writing committee — M.N. Oxman (chair), R.D. Arbeit, L.D. Gelb, G.R. Johnson, M.J. Levin, K.E. Schmader, S.E. Straus, M.S. Simberkoff; Planning and executive committees — M.N. Oxman (chair), R.D. Arbeit, P. Barry, C.E. Beisel, K.D. Boardman, C.L. Colling, L.E. Davis, L.D. Gelb, A.A. Gershon, A.R. Hayward, M.R. Irwin, G.R. Johnson, M.J. Levin, P.N. Peduzzi, K.E. Schmader, M.S. Simberkoff, S.E. Straus, A. Weinberg, H.M. Williams, P.W. Annunziato, C.Y. Chan, I.S.F. Chan, S. Manoff, C.J. White; Clinical evaluation committee — L.D. Gelb, M.J. Levin, M.N. Oxman, K.E. Schmader, S.E. Straus, G.R. Johnson, H.M. Williams; Data and safety monitoring board — R. Whitley (chair), N. Blacklow, C. Crumpacker, R.H. Dworkin, J.D. Neaton, S.G. Self, J. Zaia; VACSP human rights committee, West Haven, Conn. — R. Marottoli (chair), J.C. Niederman, W. Pritchett, F. Randall, D.G. Beckwith, R.C. Feldman, W. Farrell, S. Kasl, M. Zeman, R. Mehta, H. Allore, E.B. Perry, B. Kathe, M. Coral, D. Marshall, J. Solomon; Clinical study sites (listed in descending order of the number of subjects enrolled) — Minneapolis VA Medical Center, Minneapolis: V.A. Morrison (principal investigator), D.L. Condon, G.J. Kayser, T. Knutson, E. Lorenz, R. Mahlum, S. St. Marie; VA San Diego Healthcare System, San Diego, Calif.: J.C. Guatelli, P.A. Brooks (principal investigators), D.J. Beck, B.J. Blood, R. Bourne, J. Hutsell, S. Johns, A.D. Lucko, P. McCook, D. Ram, S.L. Smith; Durham VA Medical Center, Durham, N.C.: K.E. Schmader (principal investigator), T. Alexander-Howard, L. Folsom, N. Hampshire, J. Smith, V. Willi; University of Colorado Health Sciences Center, Denver: M.J. Levin (principal investigator), D. Barber, J. Block, N. Lang, L. Murray, S. Narro; VA Ann Arbor Healthcare System, Ann Arbor, Mich.: C.A. Kauffman (principal investigator), M. Ford, D. Hammer, M. Pesti, J.P. Thompson; Edward Hines Jr. VA Hospital, Chicago: C.T. Pachucki (principal investigator), J. Leal, M. Poly Samuel, D. Terry, N. Villanueva, S. Wood; VA Puget Sound Healthcare System, Seattle: K.M. Neuzil (principal investigator), P. Cleary, K. Greer, J. M. Laguire, K. Margulies, M. Moroz, J.A. Zuydhoek Nicholas; St. Louis VA Medical Center, St. Louis: L. Gelb (principal investigator), C. Bodicky, E.A. Clark, L. Conwill, R.E. Davis, C. Goessling; New Mexico VA Healthcare System, Albuquerque: L.E. Davis, M.K. King (principal investigators), M. Bowles, M. Estrada, K. Falkenberg, A. Garduno, J.E. Jones; University of Rochester Medical Center, Rochester, N.Y.: R.F. Betts (principal investigator), E. Barker, B. Fernaays, B. Mahoney, J. Marianacci; Vanderbilt University Medical Center, Nashville: P.F. Wright, M.R. Griffin (principal investigators), P. Chapin, L. Craddock, T. McMinn, C. Meisch, B. Redd, C. Robbins, J.Sanders; National Institutes of Health, Bethesda, Md.: P. Brunell, N.E. Soto, A.R. Marques (principal investigators), C. Groden, P. Hohman, C. Jones, M. Kelly, R. McCown, E. Meshesha, M. Raj, V. Koneti Rao; Baltimore VA Medical Center, Baltimore: S.K. Keay (principal investigator), C. Boyce, T. Bremer, K.B. Haymart, N.D. Lamb, J. Murray; VA Boston Healthcare System, Boston: R.D. Arbeit, R.P. Goodman, D.J. Cotton (principal investigators), J. Ambrosino, M. Campasano, I. Cook, D.J. Cowan, S.A. Davis, Jr., B. Dionian, C. Flemming, R.Serrao, J. Strymish, D. Syat; Birmingham VA Medical Center, Birmingham, Ala.: J.W. Gnann, Jr. (principal investigator), L. Davis, M.S. Holloway, J. Moody, P. Pappas, T. Reynolds, M. Salvaggio, N. Story, L.J. Williams; VA Palo Alto Healthcare System, Palo Alto, Calif.: J. Loutit, M. Holodniy (principal investigators), D. Cowley, S.C. Ezeji-Okoye, V.L. Faria, K.F. Kodair, S.M. Rios; Baylor College of Medicine, Houston: W.A. Keitel (principal investigator), C.B. Dyer, H. El-Sahli, R.J. Hamill, P. Holder, K. Humphrey, I. Leonard, C. Tajonera, J. Wells; VA New York Harbor Healthcare System (New York campus), New York: M.S. Simberkoff (principal investigator), J.P. Adams, S. Diaz, D. Head, M.M. Lacher; University of Texas Health Science Center San Antonio, San Antonio: G.E. Crawford (principal investigator), S. Andrews, S. Campbell, D. Hicks, C. Revado, P. Shope, K. Summers; Northport VA Medical Center, Northport, N.Y.: S. Yeh, V.E. Jimenez, Z. Lobo (principal investigators), S. Chien, L. Donnelly, B. Lorenzo, S. Lovitt, J.M. Schanfeld, M.C. Stanganelli, A. Zias; James A. Haley Veterans Hospital, Tampa, Fla.: J.F. Toney (principal investigator), J. Kirk, D. Kuziel, R. Morales, J.H. Stocks, M. Walker; Lexington VA Medical Center, Lexington, Ky.: R.N. Greenberg (principal investigator), J. Cox, K. Damron, L. Danko, N. Johnson, D. Meade, T.R. Mucci, J. Peake; VA Cooperative Studies Program Coordinating Center, VA Connecticut Healthcare System, West Haven: G.R. Johnson (study biostatistician), M. Antonelli, D. Collins, P. Collins, R. Concepcion, C. Cushing, K.. Dellert, K. DiBenedetto, A. Hudson, B.J. Huff, T.C. Kyriakides, K. Newvine, P. O'Brien, V. McBride, S. O'Neil, P.N. Peduzzi, J. Vitale, T. Warholak, D. Wood, J.H. Zhang; VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, N.M.: K.D. Boardman, C.L. Colling, B. Del Curto, R.W. Fetter, J. Peterson, M.R. Sather; VA Office of Research and Development, Washington, D.C.: D. Deykin, J. Feussner, S. Fihn, B. Schuster, P. Lavori, S. Berkowitz, J. Gough, G. Huang; Study chair's office, VA San Diego Healthcare System, San Diego, Calif.: M.N. Oxman (study chair), H.M. Williams (national study coordinator), A.E. Kendall, S. Markum, J. Pettiford; Central Diagnostic Laboratory VA San Diego Healthcare System, San Diego, Calif.: R. Harbecke, Y. Naidu, L.J. Wopschall; Central Cell-Mediated Immunity Laboratory, University of Colorado Health Sciences Center, Denver: A.R. Hayward, A. Weinberg, D. Elizabeth, L. Enomoto, M. Jones; Central Cell-Mediated Immunity Laboratory, San Diego VA Healthcare System, San Diego, Calif.: H.A. Stanley, P. Jordan; Merck Research Laboratories, West Point, Pa.: K. Abraham, K. Adair, L. Amornwichet, P. Annunziato, D. Anzalone, B. Arnold, N. Brown, P. Brownell, M. Bulotsky, M. Caulfield, C.Y. Chan, I.S.F. Chan, F. Chen, C. Cheney, K. Chirgwin, J. Chodakewitz, S. Ci, J. Clair, K. Coll, S. Cook, P. Coplan, D. Cromley, C. Durkan, L. Eaton, J. Field, T. Fitzgerald, J. Ginanni, E. Giuliani, C. Gracin, D. Gutsch, A. Harmon, K. Hencken, J. Heyse, L. Hostelley, C. Ip, H. Joseph, J. Kang, R. Kaufhold, P.M. Keller, B. Lang, L. Levit, S. Lewis, S. Li, J. Liu, J. Lou, R. Lowry, S. Manoff, R. Marchese, H. Matthews, T. Morley, K. Murray, A. Ngai, A. Nikas, C. O'Brien, G. Pannicke, N. Patel, K. Perrin, L. Petruhkin, S. Ptyza, J. Rafter, V. Rednar, B. Rich, L. Rubinstein, K. Russell, R. Rutledge, J. Ryan, P. Saddier, J. Sadoff, K. Schlienger, F. Schödel, S. Senior, A. Shaw, T. Sheehan, J. Silber, J. Smith, Y. Su, T. Sterling, D. Stinson, S. Sutradhar, M.E. Thompson, R. Vessey, H. Wang, J. Wang, W. Wang, R. Wasserman, M. Waters, D. Weiss, C.J. White, M. Wooters, J. Xu; Study monitoring — Covalent Group, Wayne, Pa; VACSP Good Clinical Practice Monitoring (SMART), Albuquerque, N.M.: C. Haakenson, C. Colling, D. Krueger, and L. Taylor.
- References
References
1
Head H ,Campbell AW . The pathology of herpes zoster and its bearing on sensory localization. Brain 1900;23:353-523
CrossRef | Web of Science2
Gnann JW Jr ,Whitley RJ . Herpes zoster. N Engl J Med 2002;347:340-346
Free Full Text | Web of Science | Medline3
Hope-Simpson RE . The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965;58:9-20
Medline4
Weller TH . Varicella and herpes zoster: changing concepts of the natural history, control, and importance of a not-so-benign virus. N Engl J Med 1983;309:1434-1440
Full Text | Web of Science | Medline5
Oxman MN. Clinical manifestations of herpes zoster. In: Arvin AM, Gershon AA, eds. Varicella zoster virus: virology and clinical management. Cambridge, England: Cambridge University Press, 2000:246-75.
6
Burgoon CF Jr ,Burgoon JS ,Baldridge GD . The natural history of herpes zoster. JAMA 1957;164:265-269
Web of Science | Medline7
Ragozzino MW ,Melton LF III ,Kurland LT ,Chu CP ,Perry HO . Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982;61:310-316
Web of Science | Medline8
Donahue JG ,Choo PW ,Manson JE ,Platt R . The incidence of herpes zoster. Arch Intern Med 1995;155:1605-1609
CrossRef | Web of Science | Medline9
Dworkin RH ,Portenoy RK . Pain and its persistence in herpes zoster. Pain 1996;67:241-251
CrossRef | Web of Science | Medline10
Hope-Simpson RE . Postherpetic neuralgia. J R Coll Gen Pract 1975;25:571-575
Medline11
Kost RG ,Straus SE . Postherpetic neuralgia -- pathogenesis, treatment, and prevention. N Engl J Med 1996;335:32-42
Full Text | Web of Science | Medline12
Lydick E ,Epstein RS ,Himmelberger D ,White CJ . Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology 1995;45:Suppl 8:S52-S53
Web of Science | Medline13
Dworkin RH ,Schmader KE . The treatment and prevention of postherpetic neuralgia. Clin Infect Dis 2003;36:877-882
CrossRef | Web of Science | Medline14
Dolin R ,Reichman RC ,Mazur MH ,Whitley RJ . NIH conference: herpes zoster-varicella infections in immunosuppressed patients. Ann Intern Med 1978;89:375-388
Web of Science | Medline15
Galil K ,Choo PW ,Donahue JG ,Platt R . The sequelae of herpes zoster. Arch Intern Med 1997;157:1209-1213
CrossRef | Web of Science | Medline16
Wilson A ,Sharp M ,Koropchak CM ,Ting SF ,Arvin AM . Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 1992;165:119-126
CrossRef | Web of Science | Medline17
Buchbinder SP ,Katz MH ,Hessol NA , et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992;166:1153-1156
CrossRef | Web of Science | Medline18
Miller AE . Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology 1980;30:582-587
Web of Science | Medline19
Berger R ,Florent G ,Just M . Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infect Immun 1981;32:24-27
Web of Science | Medline20
Burke BL ,Steele RW ,Beard OW ,Wood JS ,Cain TD ,Marmer DJ . Immune response to varicella-zoster in the aged. Arch Intern Med 1982;142:291-293
CrossRef | Web of Science | Medline21
Levin MJ ,Murray M ,Rotbart HA ,Zerbe GO ,White J ,Hayward AR . Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 1992;166:253-259
CrossRef | Web of Science | Medline22
Oxman MN . Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 1995;45:Suppl 8:S41-S46
Web of Science | Medline23
Levin MJ ,Barber D ,Goldblatt E , et al. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis 1998;178:Suppl 1:S109-S112
CrossRef | Web of Science | Medline24
Levin MJ ,Smith JG ,Kaufhold RM , et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003;188:1336-1344
CrossRef | Web of Science | Medline25
Trannoy E ,Berger R ,Hollander G , et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine 2000;18:1700-1706
CrossRef | Web of Science | Medline26
Redman RL ,Nader S ,Zerboni L , et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis 1997;176:578-585
CrossRef | Web of Science | Medline27
Hata A ,Asanuma H ,Rinki M , et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002;347:26-34
Free Full Text | Web of Science | Medline28
Coplan PM ,Schmader K ,Nikas A , et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004;5:344-356
CrossRef | Web of Science | Medline29
Ware J Jr ,Kosinski M ,Keller SD . A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-233
CrossRef | Web of Science | Medline30
Brazier J ,Jones N ,Kind P . Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 1993;2:169-180
CrossRef | Web of Science | Medline31
Chang MN ,Guess HA ,Heyse JF . Reduction in burden of illness: a new efficacy measure for prevention trials. Stat Med 1994;13:1807-1814
CrossRef | Web of Science | Medline32
Lydick E ,Epstein RS ,Himmelberger D ,White CJ . Area under the curve: a metric for patient subjective responses in episodic diseases. Qual Life Res 1995;4:41-45
CrossRef | Web of Science | Medline33
Daut RL ,Cleeland CS ,Flanery RC , et al. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983;17:197-210
CrossRef | Web of Science | Medline34
Guess HA ,Lydick EG ,Small RD ,Miller LP . Epidemiologic programs for computers and calculators: exact binomial confidence intervals for the relative risk in follow-up studies with sparsely stratified incidence density data. Am J Epidemiol 1987;125:340-347
Web of Science | Medline35
Guess HA ,Thomas JE . A rapidly converging algorithm for exact binomial confidence intervals about the relative risk in follow-up studies with stratified incidence-density data. Epidemiology 1990;1:75-77
CrossRef | Medline36
Martin DO ,Austin H . Exact estimates for a rate ratio. Epidemiology 1996;7:29-33
CrossRef | Web of Science | Medline37
Hochberg Y . A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-802
CrossRef | Web of Science38
Miettinen O ,Nurminen M . Comparative analysis of two rates. Stat Med 1985;4:213-226
CrossRef | Web of Science | Medline
- Citing Articles (519)
Citing Articles
1
Dai Watanabe, Naruhito Otani, Sachiko Suzuki, Hiromi Dohi, Kazuyuki Hirota, Hitoshi Yonemoto, Yusuke Koizumi, Hiroshi Otera, Keishiro Yajima, Yasuharu Nishida, Tomoko Uehira, Masayuki Shima, Takuma Shirasaka, Toshiomi Okuno. (2013) Evaluation of VZV-specific cell-mediated immunity in adults infected with HIV-1 by using a simple IFN-γ release assay. Journal of Medical Virology 85:8, 1313-1320
2
A. Moanna, D. Rimland. (2013) Decreasing Incidence of Herpes Zoster in the Highly Active Antiretroviral Therapy Era. Clinical Infectious Diseases 57:1, 122-125
3
Mustafa Kosker, Fulya Duman, Kunal Suri, Kristin M. Hammersmith, Parveen K. Nagra, Christopher J. Rapuano. (2013) Long-term Results of Keratoplasty in Patients With Herpes Zoster Ophthalmicus. Cornea 32:7, 982-986
4
Zachary Elkin, Elisabeth J. Cohen, Judith D. Goldberg, Colleen Gillespie, Xiaochun Li, Jesse Jung, Michael Cohen, Lisa Park, Michael H. Perskin. (2013) Studying Physician Knowledge, Attitudes, and Practices Regarding the Herpes Zoster Vaccine to Address Perceived Barriers to Vaccination. Cornea 32:7, 976-981
5
Barbara P. Yawn, Peter C. Wollan, Jennifer L. St. Sauver, Linda C. Butterfield. (2013) Herpes Zoster Eye Complications: Rates and Trends. Mayo Clinic Proceedings 88:6, 562-570
6
Bharath Manu Akkara Veetil, Elena Myasoedova, Eric L. Matteson, Sherine E. Gabriel, Abigail B. Green, Cynthia S. Crowson. (2013) Incidence and Time Trends of Herpes Zoster in Rheumatoid Arthritis: A Population-Based Cohort Study. Arthritis Care & Research 65:6, 854-861
7
C J Forlenza, T N Small. (2013) Live (vaccines) from New York. Bone Marrow Transplantation 48:6, 749-754
8
Rajiv Lingaraju, Michael A Ashburn. (2013) Pain management in the elderly. Aging Health 9:3, 265-274
9
H. J. Field, R. A. Vere Hodge. (2013) Recent developments in anti-herpesvirus drugs. British Medical Bulletin 106:1, 213-249
10
Xavier Bresse, Lieven Annemans, Emmanuelle Préaud, Karine Bloch, Gérard Duru, Aline Gauthier. (2013) Vaccination against herpes zoster and postherpetic neuralgia in France: a cost–effectiveness analysis. Expert Review of Pharmacoeconomics & Outcomes Research 13:3, 393-406
11
Abigail R. Cogman, Eliza F. Chakravarty. (2013) The case for Zostavax vaccination in systemic lupus erythematosus. Vaccine
12
Gérard Mick, Guy Hans. (2013) Postherpetic neuralgia in Europe: The scale of the problem and outlook for the future. Journal of Clinical Gerontology and Geriatrics
13
Stephanie Frisch, Aibing Mary Guo. (2013) Diagnostic Methods and Management Strategies of Herpes Simplex and Herpes Zoster Infections. Clinics in Geriatric Medicine 29:2, 501-526
14
Gang Xu, Zhong-Wei Lv, Yan Feng, Wei-Zhen Tang, Gang Xiao Xu. (2013) A Single-Center Randomized Controlled Trial of Local Methylcobalamin Injection for Subacute Herpetic Neuralgia. Pain Medicinen/a-n/a
15
Jesse J. Jung, Zachary P. Elkin, Xiaochun Li, Judith D. Goldberg, Aimée R. Edell, Michael N. Cohen, Kevin C. Chen, Michael H. Perskin, Lisa Park, Elisabeth J. Cohen. (2013) Increasing Use of the Vaccine Against Zoster Through Recommendation and Administration by Ophthalmologists at a City Hospital. American Journal of Ophthalmology 155:5, 787-795.e2
16
Werner JD Ouwendijk, Kerry J Laing, Georges MGM Verjans, David M Koelle. (2013) T-cell immunity to human alphaherpesviruses. Current Opinion in Virology
17
Daniel O Villarreal, Kendra T Talbott, Daniel K Choo, Devon J Shedlock, David B Weiner. (2013) Synthetic DNA vaccine strategies against persistent viral infections. Expert Review of Vaccines 12:5, 537-554
18
Wendy S. Hupp, F. John Firriolo. (2013) Cranial Neuralgias. Dental Clinics of North America
19
Timothy Smith, Allitia DiBernardo, Yingqi Shi, Mike J. Todd, H. Robert Brashear, Lisa M. Ford. (2013) Efficacy and Safety of Carisbamate in Patients with Diabetic Neuropathy or Postherpetic Neuralgia: Results from 3 Randomized, Double-Blind Placebo-Controlled Trials. Pain Practicen/a-n/a
20
V. A. Morrison, M. N. Oxman, M. J. Levin, K. E. Schmader, J. C. Guatelli, R. F. Betts, L. D. Gelb, C. T. Pachucki, S. K. Keay, B. Menzies, M. R. Griffin, C. A. Kauffman, A. R. Marques, J. F. Toney, M. S. Simberkoff, R. Serrao, R. D. Arbeit, J. W. Gnann, R. N. Greenberg, M. Holodniy, W. A. Keitel, S. S. Yeh, L. E. Davis, G. E. Crawford, K. M. Neuzil, G. R. Johnson, J. H. Zhang, R. Harbecke, I. S. F. Chan, P. M. Keller, H. M. Williams, K. D. Boardman, J. L. Silber, P. W. Annunziato, . (2013) Safety of Zoster Vaccine in Elderly Adults Following Documented Herpes Zoster. Journal of Infectious Diseases
21
M. R. Irwin, M. J. Levin, M. L. Laudenslager, R. Olmstead, A. Lucko, N. Lang, C. Carrillo, H. A. Stanley, M. J. Caulfield, A. Weinberg, I. S. F. Chan, J. Clair, J. G. Smith, R. D. Marchese, H. M. Williams, D. J. Beck, P. T. McCook, J. H. Zhang, G. Johnson, M. N. Oxman. (2013) Varicella Zoster Virus-Specific Immune Responses to a Herpes Zoster Vaccine in Elderly Recipients With Major Depression and the Impact of Antidepressant Medications. Clinical Infectious Diseases 56:8, 1085-1093
22
Y. OKUNO, Y. TAKAO, Y. MIYAZAKI, F. OHNISHI, M. OKEDA, S. YANO, H. KUMIHASHI, Y. GOMI, K. MAEDA, T. ISHIKAWA, Y. MORI, H. ASADA, H. ISO, K. YAMANISHI. (2013) Assessment of skin test with varicella-zoster virus antigen for predicting the risk of herpes zoster. Epidemiology and Infection 141:04, 706-713
23
Joseph R. Berger. (2013) Varicella vaccination after fingolimod: A case report. Multiple Sclerosis and Related Disorders
24
Takao Ozaki. (2013) Varicella vaccination in Japan: necessity of implementing a routine vaccination program. Journal of Infection and Chemotherapy 19:2, 188-195
25
Paul Griffiths, Stanley Plotkin, Edward Mocarski, Robert Pass, Mark Schleiss, Philip Krause, Stephanie Bialek. (2013) Desirability and feasibility of a vaccine against cytomegalovirus. Vaccine 31, B197-B203
26
Alejandra G. Begazo Cruz. (2013) Inmunización y quimioprofilaxis en pacientes con artritis reumatoide. Seminarios de la Fundación Española de Reumatología 14:2, 36-42
27
Atsuko Hata, Fukue Inoue, Midori Yamasaki, Jun Fujikawa, Yukiko Kawasaki, Yoshiyuki Hamamoto, Sachiko Honjo, Eiko Moriishi, Yasuko Mori, Hiroyuki Koshiyama. (2013) Safety, humoral and cell-mediated immune responses to herpes zoster vaccine in subjects with diabetes mellitus. Journal of Infection
28
Emily Yiping Gan, Elizabeth Ai Lian Tian, Hong Liang Tey. (2013) Management of Herpes Zoster and Post-Herpetic Neuralgia. American Journal of Clinical Dermatology 14:2, 77-85
29
Haatem Reda, Kaitlin Greene, Frank L. Rice, Michael C. Rowbotham, Karin L. Petersen. (2013) Natural History of Herpes Zoster: Late follow-up 3.9yrs (n=43) and 7.7yrs (n=10). PAIN
30
Hideo Asada, Kousuke Nagayama, Aiko Okazaki, Yasuko Mori, Yoshinobu Okuno, Yukiko Takao, Yoshiyuki Miyazaki, Fumitake Onishi, Masayuki Okeda, Shuichiro Yano, Hideaki Kumihashi, Yasuyuki Gomi, Kazuhiro Maeda, Toyokazu Ishikawa, Hiroyasu Iso, Koichi Yamanishi. (2013) An inverse correlation of VZV skin-test reaction, but not antibody, with severity of herpes zoster skin symptoms and zoster-associated pain. Journal of Dermatological Science 69:3, 243-249
31
Meghan W. Macomber, Kathleen M. Mullane, Stanley L. Liauw. (2013) Herpes zoster and radiation therapy: What radiation oncologists need to know about diagnosing, preventing, and treating herpes zoster. Practical Radiation Oncology
32
G.S. Goldman, P.G. King. (2013) Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data. Vaccine 31:13, 1680-1694
33
Jay Halbert, Phyllis Kozarsky, Jane Chiodini, Nicholas Zwar, Gary Brunette, Jane N. Zuckerman. Vaccine-Preventable Disease. In: Principles and Practice of Travel Medicine. Wiley-Blackwell, 2013:209-259.
34
Paul Kinchington. Changes Associated with CNS Infections Caused by the Herpesvirus Varicella Zoster Virus (VZV) and Models of VZV Neurotropism. In: Neuroviral Infections. CRC Press, 2013:215-244.
35
Antonio Volpi, Francesca Pica. Epstein–Barr Virus and CNS Infections. In: Neuroviral Infections. CRC Press, 2013:245-272.
36
J. A. Fishman. (2013) Overview: Cytomegalovirus and the Herpesviruses in Transplantation. American Journal of Transplantation 13:s3, 1-8
37
R. A. Zuckerman, A. P. Limaye. (2013) Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV) in Solid Organ Transplant Patients. American Journal of Transplantation 13:s3, 55-66
38
Sébastien Krypciak, Anthony Mézière, Joël Belmin, Stéphane Herbaud, Elena Paillaud. (2013) Quelle prévention vaccinale et cardiovasculaire peut-on conseiller aux sujets âgés ?. La Presse Médicale 42:2, 202-208
39
Thomas D. Szucs, Alena M. Pfeil. (2013) A Systematic Review of the Cost Effectiveness of Herpes Zoster Vaccination. PharmacoEconomics 31:2, 125-136
40
Pieter T. de Boer, Koen B. Pouwels, Juul M. Cox, Eelko Hak, Jan C. Wilschut, Maarten J. Postma. (2013) Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine 31:9, 1276-1283
41
M. Fahlbusch, U. Wesselmann, P. Lehmann. (2013) Herpes zoster nach Varicella-Zoster-Virus-Impfung. Der Hautarzt 64:2, 107-109
42
Marie Studahl, Lars Lindquist, Britt-Marie Eriksson, Göran Günther, Malin Bengner, Elisabeth Franzen-Röhl, Jan Fohlman, Tomas Bergström, Elisabeth Aurelius. (2013) Acute Viral Infections of the Central Nervous System in Immunocompetent Adults: Diagnosis and Management. Drugs 73:2, 131-158
43
G. Atma Vemulakonda, Jay S. Pepose, Russell N. Van Gelder. Acute Retinal Necrosis Syndrome. In: Retina. Elsevier, 2013:1523-1531.
44
M. Anthony Moody. Microbial Vaccine Development. In: Genomic and Personalized Medicine. Elsevier, 2013:1119-1128.
45
You Ra Kim, Nam Chun Cho, In Cheon You. (2013) Comparison of Herpes Zoster Ophthalmicus in Patients 60 Years Older Versus Younger than 60 Years. Journal of the Korean Ophthalmological Society 54:4, 568
46
Renske Eilers, Paul FM Krabbe, Ted GA van Essen, Anita Suijkerbuijk, Alies van Lier, Hester E de Melker. (2013) Assessment of vaccine candidates for persons aged 50 and older: a review. BMC Geriatrics 13:1, 32
47
Wayne L. Gray. (2013) Recombinant Varicella-Zoster Virus Vaccines as Platforms for Expression of Foreign Antigens. Advances in Virology 2013, 1-8
48
Anne A. Gershon. (2013) Varicella zoster vaccines and their implications for development of HSV vaccines. Virology 435:1, 29-36
49
Bernhard Ultsch, Ingrid Köster, Thomas Reinhold, Anette Siedler, Gérard Krause, Andrea Icks, Ingrid Schubert, Ole Wichmann. (2012) Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. The European Journal of Health Economics
50
Jen-Yin Chen, Chia-Yu Chang, Yung-Song Lin, Miao-Lin Hu. (2012) Nutritional Factors in Herpes Zoster, Postherpetic Neuralgia, and Zoster Vaccination. Population Health Management 15:6, 391-397
51
Garret Cullen, Rachel P. Baden, Adam S. Cheifetz. (2012) Varicella zoster virus infection in inflammatory bowel disease. Inflammatory Bowel Diseases 18:12, 2392-2403
52
M. D. Long, C. Martin, R. S. Sandler, M. D. Kappelman. (2012) Increased risk of Herpes zoster among 108 604 patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeuticsn/a-n/a
53
Megan Steain, Barry Slobedman, Allison Abendroth. (2012) The host immune response to varicella zoster virus. Future Virology 7:12, 1205-1220
54
K. E. Schmader, M. N. Oxman, M. J. Levin, G. Johnson, J. H. Zhang, R. Betts, V. A. Morrison, L. Gelb, J. C. Guatelli, R. Harbecke, C. Pachucki, S. Keay, B. Menzies, M. R. Griffin, C. Kauffman, A. Marques, J. Toney, P. M. Keller, X. Li, I. S. F. Chan, P. Annunziato, . (2012) Persistence of the Efficacy of Zoster Vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy. Clinical Infectious Diseases 55:10, 1320-1328
55
Chang R. Na, Steven Wang, Robert S. Kirsner, Daniel G. Federman. (2012) Elderly Adults and Skin Disorders. Southern Medical Journal 105:11, 600-606
56
Anna MZ Gagliardi, Brenda Nazaré Gomes Silva, Maria R Torloni, Bernardo GO Soares, Anna MZ Gagliardi. Vaccines for preventing herpes zoster in older adults. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2012.
57
I. Leroux-Roels, G. Leroux-Roels, F. Clement, P. Vandepapeliere, V. Vassilev, E. Ledent, T. C. Heineman. (2012) A Phase 1/2 Clinical Trial Evaluating Safety and Immunogenicity of a Varicella Zoster Glycoprotein E Subunit Vaccine Candidate in Young and Older Adults. Journal of Infectious Diseases 206:8, 1280-1290
58
Tim Bongartz, Robert Orenstein. (2012) Immunology: Zoster vaccine and biologic agents: time to question a paradigm?. Nature Reviews Rheumatology 8:11, 636-638
59
A. Mahamud, M. Marin, S. P. Nickell, T. Shoemaker, J. X. Zhang, S. R. Bialek. (2012) Herpes Zoster-Related Deaths in the United States: Validity of Death Certificates and Mortality Rates, 1979-2007. Clinical Infectious Diseases 55:7, 960-966
60
Riduan M. Joesoef, Rafael Harpaz, Jessica Leung, Stephanie R. Bialek. (2012) Chronic Medical Conditions as Risk Factors for Herpes Zoster. Mayo Clinic Proceedings 87:10, 961-967
61
B. Weinberger, B. Grubeck-Loebenstein. (2012) Vaccines for the elderly. Clinical Microbiology and Infection 18, 100-108
62
Leah J. Blank, Michael J. Polydefkis, Richard D. Moore, Kelly A. Gebo. (2012) Herpes Zoster Among Persons Living With HIV in the Current Antiretroviral Therapy Era. JAIDS Journal of Acquired Immune Deficiency Syndromes 61:2, 203-207
63
M. Labetoulle, T. Bourcier. (2012) Zona ophtalmique et atteintes du segment antérieur de l’œil. EMC - Ophtalmologie 9:4, 1-7
64
Ewa Gawecka, Oddbjørn Viken. (2012) Postherpetic neuralgia: New hopes in prevention with adult vaccination and in treatment with a concentrated capsaicin patch. Scandinavian Journal of Pain 3:4, 220-228
65
Mei-Yi Wu, Yung-Ho Hsu, Chien-Ling Su, Yuh-Feng Lin, Hui-Wen Lin. (2012) Risk of Herpes Zoster in CKD: A Matched-Cohort Study Based on Administrative Data. American Journal of Kidney Diseases 60:4, 548-552
66
Guangjin Li, Mingcan Yu, Won-Woo Lee, Michael Tsang, Eswar Krishnan, Cornelia M Weyand, Jörg J Goronzy. (2012) Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity. Nature Medicine 18:10, 1518-1524
67
Huamin Tang, Eiko Moriishi, Shigefumi Okamoto, Yoshinobu Okuno, Hiroyasu Iso, Hideo Asada, Koichi Yamanishi, Yasuko Mori. (2012) A community-based survey of varicella-zoster virus-specific immune responses in the elderly. Journal of Clinical Virology 55:1, 46-50
68
Charles E Argoff, Cuiping Chen, Verne E Cowles. (2012) Clinical development of a once-daily gastroretentive formulation of gabapentin for treatment of postherpetic neuralgia: an overview. Expert Opinion on Drug Delivery 9:9, 1147-1160
69
Roger Baxter, Trung Nam Tran, John Hansen, Michael Emery, Bruce Fireman, Joan Bartlett, Ned Lewis, Patricia Saddier. (2012) Safety of Zostavax™—A cohort study in a managed care organization. Vaccine
70
KAREN L. KIMM. (2012) Q: Should I get the shingles vaccine?. Journal of the American Academy of Physician Assistants 25:9, 65
71
Kati Lukas, Alexander Edte, Isabelle Bertrand. (2012) The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries. Journal of Public Health 20:4, 441-451
72
Jessica Robinson-Papp, Ik Lin Tan, David M. Simpson. (2012) Neuromuscular complications in HIV: effects of aging. Journal of NeuroVirology 18:4, 331-338
73
T. Schmid, S. Pautex, P.O. Lang. (2012) Douleurs zostériennes : une prise en charge adaptée à la personne âgée. NPG Neurologie - Psychiatrie - Gériatrie 12:70, 157-162
74
Andrew J. Fabiano, Carolyn Doyle, Robert J. Plunkett. (2012) Intrathecal Medications in Post-Herpetic Neuralgia. Pain Medicine 13:8, 1088-1090
75
Myron J Levin. (2012) Immune senescence and vaccines to prevent herpes zoster in older persons. Current Opinion in Immunology 24:4, 494-500
76
H. F. Tseng, M. Chi, N. Smith, S. M. Marcy, L. S. Sy, S. J. Jacobsen. (2012) Herpes Zoster Vaccine and the Incidence of Recurrent Herpes Zoster in an Immunocompetent Elderly Population. Journal of Infectious Diseases 206:2, 190-196
77
Aileen Sy, Stephen D. McLeod, Elisabeth J. Cohen, Todd P. Margolis, Mark J. Mannis, Thomas M. Lietman, Nisha R. Acharya. (2012) Practice Patterns and Opinions in the Management of Recurrent or Chronic Herpes Zoster Ophthalmicus. Cornea 31:7, 786-790
78
Mark A. Supiano, Cathy Alessi, Ronni Chernoff, Andrew Goldberg, John E. Morley, Kenneth E. Schmader, Kenneth Shay, . (2012) Department of Veterans Affairs Geriatric Research, Education and Clinical Centers: Translating Aging Research into Clinical Geriatrics. Journal of the American Geriatrics Society 60:7, 1347-1356
79
Judith Thomas-Crusells, Janet E. McElhaney, M. Teresa Aguado. (2012) Report of the ad-hoc consultation on aging and immunization for a future WHO research agenda on life-course immunization. Vaccine
80
P.O. Lang, J.-P. Michel. (2012) Se faire vacciner après 60 ans : pourquoi et comment ?. NPG Neurologie - Psychiatrie - Gériatrie 12:69, 103-110
81
Angela L. Funovits, Kyle L. Wagamon, Eliot N. Mostow, Robert T. Brodell. (2012) Refusal of shingles vaccine: Implications for public health. Journal of the American Academy of Dermatology 66:6, 1011-1012
82
Werner J. D. Ouwendijk, Sarah E. Flowerdew, Desiree Wick, Anja K. E. Horn, Inga Sinicina, Michael Strupp, Albert D. M. E. Osterhaus, Georges M. G. M. Verjans, Katharina Hüfner. (2012) Immunohistochemical detection of intra-neuronal VZV proteins in snap-frozen human ganglia is confounded by antibodies directed against blood group A1-associated antigens. Journal of NeuroVirology 18:3, 172-180
83
Namita Vilas Nasare, Pravin Suryakantrao Deshmukh, Basu Dev Banerjee, Pramod Kumari Mediratta, Rafat S Ahmed, Ashok Kumar Saxena, Sambit Nath Bhattacharya. (2012) CYP2D6*4 polymorphism, tramadol treatment and its clinical impact in patients with postherpetic neuralgia. Personalized Medicine 9:4, 371-385
84
Roman Chlibek, Ioana Anca, Francis Andre, Milan Čižman, Inga Ivaskeviciene, Atanas Mangarov, Zsófia Mészner, Penka Perenovska, Marko Pokorn, Roman Prymula, Darko Richter, Nuran Salman, Pavol Šimurka, Eda Tamm, Goran Tešović, Ingrid Urbancikova, Dace Zavadska, Vytautas Usonis. (2012) Szczepienia dorosłych w 11 krajach Europy Środkowej – kalendarze szczepień nie tylko dla wieku dziecięcego. Pediatria Polska 87:3, I-XX
85
Gordon Irving. (2012) Once-daily gastroretentive gabapentin for treatment of postherpetic neuralgia. Pain Management 2:3, 259-265
86
Najoua Dendouga, Michel Fochesato, Laurence Lockman, Sally Mossman, Sandra L. Giannini. (2012) Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine 30:20, 3126-3135
87
M. Yu, G. Li, W.-W. Lee, M. Yuan, D. Cui, C. M. Weyand, J. J. Goronzy. (2012) PNAS Plus: Signal inhibition by the dual-specific phosphatase 4 impairs T cell-dependent B-cell responses with age. Proceedings of the National Academy of Sciences
88
S. Mazière, G. Gavazzi, M. Paccalin. (2012) Fragilité et infection chez le sujet âgé : quelles relations ?. Les cahiers de l'année gérontologique
89
Vineeta Shobha. (2012) Common anti-infective prophylaxis and vaccinations in autoimmune inflammatory rheumatic diseases. Indian Journal of Rheumatology 7:1, 21-28
90
Blair H. Smith, Nicola Torrance. (2012) Epidemiology of Neuropathic Pain and Its Impact on Quality of Life. Current Pain and Headache Reports
91
Jeremy W. Bowers, Ling Zhang. Reactive Lymphadenopathy with Diffuse Paracortical Pattern-Infectious Etiology. In: Non-Neoplastic Hematopathology and Infections. John Wiley & Sons, Inc., 2012:323-346.
92
Miguel R Sanchez, Scott B Drutman. (2012) Current topics in infectious diseases of the skin. Expert Review of Dermatology 7:1, 93-106
93
Roman Chlibek, Ioana Anca, Francis André, Milan Čižman, Inga Ivaskeviciene, Atanas Mangarov, Zsófia Mészner, Penka Perenovska, Marko Pokorn, Roman Prymula, Darko Richter, Nuran Salman, Pavol Šimurka, Eda Tamm, Goran Tešović, Ingrid Urbancikova, Dace Zavadska, Vytautas Usonis. (2012) Adult vaccination in 11 Central European countries – Calendars are not just for children. Vaccine 30:9, 1529-1540
94
H.-t. Li, S. Lu, J.-m. Liu. (2012) Herpes Zoster Vaccination in People Aged 50-59 Years. Clinical Infectious Diseases
95
K. E. Schmader, M. J. Levin, J. W. Gnann, S. A. McNeil, T. Vesikari, R. F. Betts, S. Keay, J. E. Stek, N. D. Bundick, S.-C. Su, Y. Zhao, X. Li, I. S. F. Chan, P. W. Annunziato, J. Parrino. (2012) Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 Years. Clinical Infectious Diseases
96
Harriet J. Forbes, Sara L. Thomas, Sinéad M. Langan. (2012) The Epidemiology and Prevention of Herpes Zoster. Current Dermatology Reports
97
J. BILCKE, B. OGUNJIMI, C. MARAIS, F. DE SMET, M. CALLENS, K. CALLAERT, E. VAN KERSCHAVER, J. RAMET, P. VAN DAMME, P. BEUTELS. (2012) The health and economic burden of chickenpox and herpes zoster in Belgium. Epidemiology and Infection1-14
98
Mélanie Drolet, Myron J. Levin, Kenneth E. Schmader, Robert Johnson, Michael N. Oxman, David Patrick, Simon Olivier Fournier, James A. Mansi, Marc Brisson. (2012) Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: A 6-month prospective study. Vaccine
99
Joost N. Vermeulen, Joep M.A. Lange, Stephen K. Tyring, Patrick H. Peters, Margaret Nunez, Gregory Poland, Myron J. Levin, Carrie Freeman, Ira Chalikonda, Jianjun Li, Jeffrey G. Smith, Michael J. Caulfield, Jon E. Stek, Ivan S.F. Chan, Rupert Vessey, Florian P. Schödel, Paula W. Annunziato, Katia Schlienger, Jeffrey L. Silber. (2012) Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. Vaccine 30:5, 904-910
100
Yukiko Takao, Yoshiyuki Miyazaki, Fumitake Onishi, Hideaki Kumihashi, Yasuyuki Gomi, Toyokazu Ishikawa, Yoshinobu Okuno, Yasuko Mori, Hideo Asada, Koichi Yamanishi, Hiroyasu Iso. (2012) The Shozu Herpes Zoster (SHEZ) Study: Rationale, Design, and Description of a Prospective Cohort Study. Journal of Epidemiology 22:2, 167-174
101
Shih-Yi Lin, Jiung-Hsiun Liu, Cheng-Li Lin, I-Ju Tsai, Pei-Chun Chen, Chi-Jung Chung, Yao-Lung Liu, I-Kuan Wang, Hsin-Hung Lin, Chiu-Ching Huang. (2012) A Comparison of Herpes Zoster Incidence across the Spectrum of Chronic Kidney Disease, Dialysis and Transplantation. American Journal of Nephrology 36:1, 27-33
102
Micha Löbermann, Denise Boršo, Inken Hilgendorf, Carlos Fritzsche, Uwe K. Zettl, Emil C. Reisinger. (2012) Immunization in the adult immunocompromised host. Autoimmunity Reviews 11:3, 212-218
103
M. Comba, S. Martorano-Raimundo, E. Venturino. (2012) A Cost-Effectiveness-Assessing Model of Vaccination for Varicella and Zoster. Mathematical Modelling of Natural Phenomena 7:3, 62-77
104
Haatem Reda, James C. Watson, Lyell K. Jones. (2012) Zoster-associated mononeuropathies (ZAMs): A retrospective series. Muscle & Nerven/a-n/a
105
Richard P. Usatine, Jennifer Krejci-Manwaring. Dermatology. In: Textbook of Family Medicine. Elsevier, 2012:690-730.
106
Joke Bilcke, Christiaan Marais, Benson Ogunjimi, Lander Willem, Niel Hens, Philippe Beutels. (2012) Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. Vaccine 30:3, 675-684
107
J. David Beckham, Marylou V. Solbrig, Kenneth L. Tyler. Infections of the Nervous System. In: Neurology in Clinical Practice. Elsevier, 2012:1231-1258.
108
Robert W Johnson, Kazuo Higa. (2012) Prevention of herpes zoster pain. Pain Management 2:1, 63-69
109
N.M. Khardori. (2012) Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50–59Years. Yearbook of Medicine 2012, 96-97
110
W. Lawrence Drew, Kim S. Erlich. Management of herpesvirus infections (cytomegalovirus, herpes simplex virus, and varicella-zoster virus). In: Sande's HIV/AIDS Medicine. Elsevier, 2012:433-454.
111
Neil J. Korman. Macular, Papular, Vesiculobullous, and Pustular Diseases. In: Goldman's Cecil Medicine. Elsevier, 2012:2522-2532.
112
Liyuan Ma, Ronald R. White, Siva Narayanan, Kenneth E. Schmader. (2012) Economic Burden of Herpes Zoster Among Skilled Nursing Facility Residents in the United States. Journal of the American Medical Directors Association 13:1, 54-59
113
Paul R. Kinchington, William F. Goins. (2011) Varicella zoster virus-induced pain and post-herpetic neuralgia in the human host and in rodent animal models. Journal of NeuroVirology
114
Albert J. M. van Wijck, Mark Wallace, Nagy Mekhail, Maarten van Kleef. Herpes Zoster and Post-Herpetic Neuralgia. In: Evidence-Based Interventional Pain Medicine. Wiley-Blackwell, 2011:137-144.
115
Chien-Chun Kuo, Chien-Te Lee, I-Ming Lee, Shu-Chen Ho, Chun-Yuh Yang. (2011) Risk of Herpes Zoster in Patients Treated With Long-term Hemodialysis: A Matched Cohort Study. American Journal of Kidney Diseases
116
Paul O. Hernandez, Saba Javed, Natalia Mendoza, Whitney Lapolla, Lindsey D. Hicks, Stephen K. Tyring. (2011) Family history and herpes zoster risk in the era of shingles vaccination. Journal of Clinical Virology 52:4, 344-348
117
Gitte Vrelits Sørensen, Steen Rosthøj, Morten Würtz, Tore Kristian Danielsen, Henrik Schrøder. (2011) The epidemiology of herpes zoster in 226 children with acute lymphoblastic leukemia. Pediatric Blood & Cancer 57:6, 993-997
118
Didier Bouhassira, Olivier Chassany, Jacques Gaillat, Thomas Hanslik, Odile Launay, Claude Mann, Christian Rabaud, Olivier Rogeaux, Christophe Strady. (2011) Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50years in general practice. PAIN
119
Michael Klompas, Martin Kulldorff, Yury Vilk, Stephanie R. Bialek, Rafael Harpaz. (2011) Herpes Zoster and Postherpetic Neuralgia Surveillance Using Structured Electronic Data. Mayo Clinic Proceedings 86:12, 1146-1153
120
Barbara P. Yawn. (2011) Post-Shingles Neuralgia by Any Definition Is Painful, but Is It PHN?. Mayo Clinic Proceedings 86:12, 1141-1142
121
Hengxi Chen, Jinke Li, Tao Cui, Lina Hu, Lina Hu. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2011.
122
Christine Meyer, Amelia Kerns, Alex Barron, Craig Kreklywich, Daniel N. Streblow, Ilhem Messaoudi. (2011) Simian varicella virus gene expression during acute and latent infection of rhesus macaques. Journal of NeuroVirology
123
Atika Benbernou, Mélanie Drolet, Myron J. Levin, Kenneth E. Schmader, Michael N. Oxman, Robert Johnson, David Patrick, Stéphanie Camden, James A. Mansi, Marc Brisson. (2011) Association between prodromal pain and the severity of acute herpes zoster and utilization of health care resources. European Journal of Pain 15:10, 1100-1106
124
Albert Jan van Hoek, Alessia Melegaro, Nigel Gay, Joke Bilcke, W. John Edmunds. (2011) The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. Vaccine
125
PATRICIA O'MALLEY. (2011) Just Say No to Shingles! The Zoster Vaccine. Clinical Nurse Specialist 25:6, 281-283
126
Neelofar Ghaznawi, Ajoy Virdi, Amir Dayan, Kristin M. Hammersmith, Christopher J. Rapuano, Peter R. Laibson, Elisabeth J. Cohen. (2011) Herpes Zoster Ophthalmicus: Comparison of Disease in Patients 60 Years and Older Versus Younger than 60 Years. Ophthalmology 118:11, 2242-2250
127
Saba Javed, Syed A. Javed, Stephen K. Tyring. (2011) Varicella vaccines. Current Opinion in Infectious Diseases1
128
Stefan Palmason, Francisco M. Marty, Nathaniel S. Treister. (2011) How Do We Manage Oral Infections in Allogeneic Stem Cell Transplantation and Other Severely Immunocompromised Patients?. Oral and Maxillofacial Surgery Clinics of North America 23:4, 579-599
129
M. Aubert, H. Aumaître, J. Beytout, K. Bloch, D. Bouhour, P. Callamand, C. Chave, J. Cheymol, B. Combadière, A. Dahlab, F. Denis, L. De Pontual, B. Dodet, M.-A. Dommergues, V. Dufour, A. Gagneur, J. Gaillat, J. Gaudelus, G. Gavazzi, Y. Gillet, C. Gras-le-Guen, H. Haas, T. Hanslik, I. Hau-Rainsard, S. Larnaudie, O. Launay, M. Lorrot, P. Loulergue, D. Malvy, S. Marchand, G. Picherot, D. Pinquier, C. Pulcini, C. Rabaud, F. Regnier, P. Reinert, C. Sana, C. Savagner, B. Soubeyrand, J.-L. Stephan, C. Strady. (2011) Actualités en matière de vaccination. Archives de Pédiatrie 18:11, 1234-1246
130
H. F. Tseng, A. Liu, L. Sy, S. M. Marcy, B. Fireman, E. Weintraub, J. Baggs, S. Weinmann, R. Baxter, J. Nordin, M. F. Daley, L. Jackson, S. J. Jacobsen, . (2011) Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. Journal of Internal Medicineno-no
131
Peter Tanuseputro, Brandon Zagorski, Kevin J. Chan, Jeffrey C. Kwong. (2011) Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine 29:47, 8580-8584
132
B. P. Yawn, P. Wollan, J. St. Sauver. (2011) Comparing Shingles Incidence and Complication Rates From Medical Record Review and Administrative Database Estimates: How Close Are They?. American Journal of Epidemiology 174:9, 1054-1061
133
Danelle Cayea, Elizabeth Eckstrom, Colleen Christmas. (2011) Update in Geriatric Medicine. Journal of General Internal Medicine
134
Stanley A. Plotkin, Susan L. Plotkin. (2011) The development of vaccines: how the past led to the future. Nature Reviews Microbiology 9:12, 889-893
135
M. Salleras, A. Domínguez, N. Soldevila, A. Prat, P. Garrido, N. Torner, E. Borrás, L. Salleras. (2011) Contacts with children and young people and adult risk of suffering herpes zoster. Vaccine 29:44, 7602-7605
136
M. Assi, S. Abou Antoun. (2011) Unusual neurologic manifestations of varicella zoster virus infection with the absence of rash in a kidney transplant recipient. Transplant Infectious Disease 13:5, 545-547
137
Joke Bilcke, Benson Ogunjimi, Frank Hulstaert, Pierre Van Damme, Niel Hens, Philippe Beutels. (2011) Estimating the age-specific duration of herpes zoster vaccine protection: A matter of model choice?. Vaccine
138
Ian H Frazer, Myron J Levin. (2011) Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer. Current Opinion in Virology 1:4, 268-279
139
J.R. de Juanes, P. Arrazola, A. García de Codes, C. Ariza, R. Gil, M. San Martín, A. Gil. (2011) Hospitalizaciones por herpes zoster y neuralgia postherpética en la Comunidad de Madrid, 1998–2003. Vacunas 12:4, 129-135
140
J.M. Bayas, R. Gil, A. Llupiá, C. Díez, A. Conesa, C. Ariza, A. Gil, M. San Martín. (2011) Hospitalizaciones por herpes zoster y neuralgia postherpética en Cataluña, 1998–2003. Vacunas 12:4, 122-128
141
L. Salleras, A. Domínguez, E. Borrás, N. Soldevila. (2011) Eficacia protectora de las vacunas y efectividad de las vacunaciones: Introducción a la medición de la protección directa e indirecta. Vacunas 12:4, 136-146
142
A. A. Gershon. (2011) The History and Mystery of VZV in Saliva. Journal of Infectious Diseases 204:6, 815-816
143
S. Augustine, R. A. Bonomo. (2011) Taking stock of infections and antibiotic resistance in the elderly and long-term care facilities: A survey of existingand upcoming challenges. European Journal of Microbiology and Immunology 1:3, 190-197
144
Graciela Andrei, Robert Snoeck. (2011) Emerging drugs for varicella-zoster virus infections. Expert Opinion on Emerging Drugs 16:3, 507-535
145
D. Gilden, R. Mahalingam, M. A. Nagel, S. Pugazhenthi, R. J. Cohrs. (2011) Review: The neurobiology of varicella zoster virus infection. Neuropathology and Applied Neurobiology 37:5, 441-463
146
G. Bohelay, M. Rafaa, J.-L. Caravias, M.-L. Sigal. (2011) Prise en charge symptomatique de la douleur neuropathique en dermatologie : application aux algies postzostériennes. Annales de Dermatologie et de Vénéréologie 138:8-9, 610-619
147
Lawrence R. Stanberry, Richard Strugnell. (2011) Vaccines of the future. Perspectives in Vaccinology 1:1, 151-199
148
J.-H. Kang, J.-J. Sheu, S. Kao, H.-C. Lin. (2011) Increased Risk of Multiple Sclerosis Following Herpes Zoster: A Nationwide, Population-Based Study. Journal of Infectious Diseases 204:2, 188-192
149
Gisèle Pickering, Alain Leplege. (2011) Herpes Zoster Pain, Postherpetic Neuralgia, and Quality of Life in the Elderly. Pain Practice 11:4, 397-402
150
P.-O. Lang, J.-P. Michel. (2011) Herpes zoster vaccine: What are the potential benefits for the ageing and older adults?. European Geriatric Medicine 2:3, 134-139
151
Joseph A. Nicholas, William J. Hall. (2011) Screening and Preventive Services for Older Adults. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 78:4, 498-508
152
M.J. Álvarez-Pasquín, M.L. Morató, A. Sampedro, M. San-Martín. (2011) Perception of herpes zoster in the general population. Vacunas 12:3, 86-94
153
L. Salleras. (2011) Carga del herpes zoster en España. Vacunas 12:3, 83-85
154
Wynnis L. Tom, Sheila Fallon Friedlander. Viral Exanthems. In: Harper's Textbook of Pediatric Dermatology. Wiley-Blackwell, 2011:49.1-49.21.
155
David R.P. Guay. (2011) Geriatric Pharmacotherapy Updates. The American Journal of Geriatric Pharmacotherapy 9:3, 204-210
156
D. L. Pierson, S. K. Mehta, D. Gilden, R. J. Cohrs, M. A. Nagel, D. S. Schmid, S. K. Tyring. (2011) Varicella Zoster Virus DNA at Inoculation Sites and in Saliva After Zostavax Immunization. Journal of Infectious Diseases 203:11, 1542-1545
157
Anne Louise Oaklander. (2011) Neuropathic Itch. Seminars in Cutaneous Medicine and Surgery 30:2, 87-92
158
Barbara P. Yawn, Peter C. Wollan, Marge J. Kurland, Jennifer L. St. Sauver, Patricia Saddier. (2011) Frequency of Herpes Zoster Recurrence–Reply–I. Mayo Clinic Proceedings 86:6, 586-587
159
Antonio Volpi, Antonio Gatti, Francesca Pica. (2011) Frequency of Herpes Zoster Recurrence. Mayo Clinic Proceedings 86:6, 586
160
Simone Thomas, Wolfgang Herr. (2011) Natural and adoptive T-cell immunity against herpes family viruses after allogeneic hematopoietic stem cell transplantation. Immunotherapy 3:6, 771-788
161
Hung Fu Tseng, Ning Smith, Lina S. Sy, Steven J. Jacobsen. (2011) Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine 29:20, 3628-3632
162
A. JARDINE, S. J. CONATY, H. VALLY. (2011) Herpes zoster in Australia: evidence of increase in incidence in adults attributable to varicella immunization?. Epidemiology and Infection 139:05, 658-665
163
M. Aubert, H. Aumaître, J. Beytout, K. Bloch, D. Bouhour, P. Callamand, C. Chave, J. Cheymol, B. Combadière, A. Dahlab, F. Denis, L. De Pontual, B. Dodet, M.-A. Dommergues, V. Dufour, A. Gagneur, J. Gaillat, J. Gaudelus, G. Gavazzi, Y. Gillet, C. Gras-le-Guen, H. Haas, T. Hanslik, I. Hau-Rainsard, S. Larnaudie, O. Launay, M. Lorrot, P. Loulergue, D. Malvy, S. Marchand, G. Picherot, D. Pinquier, C. Pulcini, C. Rabaud, F. Regnier, P. Reinert, C. Sana, C. Savagner, B. Soubeyrand, J.-L. Stephan, C. Strady.. (2011) Actualités en matière de vaccination. Médecine et Maladies Infectieuses 41:5, 278-290
164
Lang Kau, Cheryl A. Sadowski, Christine Hughes. (2011) Vaccinations in older adults: Focus on pneumococcal, influenza and herpes zoster infections. Canadian Pharmacists Journal 144:3, 132-141
165
Robert H. Dworkin, Christopher J. Panarites, Edward P. Armstrong, Daniel C. Malone, Sissi V. Pham. (2011) Healthcare Utilization in People with Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy. Journal of the American Geriatrics Society 59:5, 827-836
166
Michael R. Irwin, Myron J. Levin, Carmen Carrillo, Richard Olmstead, Anne Lucko, Nancy Lang, Michael J Caulfield, Adriana Weinberg, Ivan S.F. Chan, Jim Clair, Jeff G. Smith, R.D. Marchese, Heather M. Williams, Danielle J. Beck, Patricia T. McCook, Gary Johnson, Michael N. Oxman. (2011) Major depressive disorder and immunity to varicella-zoster virus in the elderly. Brain, Behavior, and Immunity 25:4, 759-766
167
Esther Sacoun. (2011) Actualités sur les nouveaux vaccins antiviraux : grippe, papillomavirus, zona. Actualités Pharmaceutiques 50:505, 38-39
168
Esther Sacoun. (2011) Actualités sur les nouveaux vaccins antiviraux : grippe, papillomavirus, zona. Option/Bio 22:450, 4-5
169
Emily Eshleman, Aamir Shahzad, Randall J Cohrs. (2011) Varicella zoster virus latency. Future Virology 6:3, 341-355
170
Trudy N Small, Morton J Cowan. (2011) Immunization of hematopoietic stem cell transplant recipients against vaccine-preventable diseases. Expert Review of Clinical Immunology 7:2, 193-203
171
Susan Fitzgerald. (2011) Herpes Zoster Vaccine Might Work Even Better Than Originally Thought. Neurology Today 11:3, 1
172
Srinivasan Sanjay, Philemon Huang, Raghavan Lavanya. (2011) Herpes Zoster Ophthalmicus. Current Treatment Options in Neurology 13:1, 79-91
173
J. Leung, R. Harpaz, N.-A. Molinari, A. Jumaan, F. Zhou. (2011) Herpes Zoster Incidence Among Insured Persons in the United States, 1993-2006: Evaluation of Impact of Varicella Vaccination. Clinical Infectious Diseases 52:3, 332-340
174
Peng-jun Lu, Gary L. Euler, Rafael Harpaz. (2011) Herpes Zoster Vaccination Among Adults Aged 60 Years and Older, in the U.S., 2008. American Journal of Preventive Medicine 40:2, e1-e6
175
S.A. Pergam, C.W. Forsberg, M.J. Boeckh, C. Maynard, A.P. Limaye, A. Wald, N.L. Smith, B.A. Young. (2011) Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients. Transplant Infectious Disease 13:1, 15-23
176
Barbara P. Yawn, Peter C. Wollan, Marge J. Kurland, Jennifer L. St. Sauver, Patricia Saddier. (2011) Herpes Zoster Recurrences More Frequent Than Previously Reported. Mayo Clinic Proceedings 86:2, 88-93
177
V. Failla, A.F. Nikkels. (2011) Ustekinumab and Herpes Zoster. Dermatology 222:2, 119-122
178
Bernhard Ultsch, Anette Siedler, Thorsten Rieck, Thomas Reinhold, Gérard Krause, Ole Wichmann. (2011) Herpes zoster in Germany: Quantifying the burden of disease. BMC Infectious Diseases 11:1, 173
179
Jie Zhang, Elizabeth Delzell, Fenglong Xie, John W Baddley, Claire Spettell, Raechele M Mcmahan, Joaquim Fernandes, Lang Chen, Kevin Winthrop, Jeffrey R Curtis. (2011) The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Research & Therapy 13:5, R174
180
R. Pesek, R. Lockey. (2011) Vaccination of adults with asthma and COPD. Allergy 66:1, 25-31
181
Christina Jensen-Dahm, Michael C Rowbotham, Haatem Reda, Karin Petersen. (2011) Effect of a single dose of pregabalin on herpes zoster pain. Trials 12:1, 55
182
Albert J. M. van Wijck, Mark Wallace, Nagy Mekhail, Maarten van Kleef. (2011) 17. Herpes Zoster and Post-Herpetic Neuralgia. Pain Practice 11:1, 88-97
183
Philip S. LaRussa, Mona Marin. Varicella-Zoster Virus Infections. In: Nelson Textbook of Pediatrics. Elsevier, 2011:1104-1110.
184
Michael Costello, Linda M. Sabatini, Margaret Yungbluth. Viral Infections. In: Henry's Clinical Diagnosis and Management by Laboratory Methods. Elsevier, 2011:1037-1064.
185
S. David Hudnall, Lawrence R. Stanberry, Paul D. Griffiths. Human Herpesvirus Infections. In: Tropical Infectious Diseases: Principles, Pathogens and Practice. Elsevier, 2011:355-368.
186
W. Barry Lee, Thomas J. Liesegang. Herpes Zoster Keratitis. In: Cornea. Elsevier, 2011:985-1000.
187
Maria A. Nagel, Don Gilden, Ravi Mahalingam, Randall J. Cohrs. Neurologic Manifestations of Herpes Zoster. In: Neuroinflammation. Elsevier, 2011:497-520.
188
Anne A. Gershon. Chickenpox, Measles, and Mumps. In: Infectious Diseases of the Fetus and Newborn. Elsevier, 2011:661-705.
189
Kenneth E. Schmader, Robert H. Dworkin. Herpes zoster and postherpetic neuralgia. In: Essentials of Pain Medicine. Elsevier, 2011:358-364.
190
Robert W. Hurley, Heidi V. Goldstein, James P. Rathmell. Painful peripheral neuropathies. In: Essentials of Pain Medicine. Elsevier, 2011:386-394.
191
Anna MZ Gagliardi, Brenda Nazaré Gomes Silva, Maria R Torloni, Bernardo Soares, Anna MZ Gagliardi. Vaccines for preventing herpes zoster in older adults. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2010.
192
Ting-Ting Wu, Marcia A. Blackman, Ren Sun. (2010) Prospects of a novel vaccination strategy for human gamma-herpesviruses. Immunologic Research 48:1-3, 122-146
193
Benoit Arnould, Khadra Benmedjahed, Jean-Luc Gallais, Patrick Giniès, Ralf Baron. (2010) The impact of herpes zoster and subsequent chronic pain on patients’ daily lives. Journal of Public Health 18:6, 567-574
194
Mark S. Wallace, Gordon Irving, Verne E. Cowles. (2010) Gabapentin Extended-Release Tablets for the Treatment of Patients with Postherpetic Neuralgia. Clinical Drug Investigation 30:11, 765-776
195
Gordon Irving. (2010) The Placebo Response. Clinical Drug Investigation 30:11, 739-748
196
S. Gonzalez Chiappe, M. Sarazin, C. Turbelin, A. Lasserre, C. Pelat, I. Bonmarin, O. Chosidow, T. Blanchon, T. Hanslik. (2010) Herpes zoster: Burden of disease in France. Vaccine 28:50, 7933-7938
197
Mélanie Drolet, Marc Brisson, Kenneth Schmader, Myron Levin, Robert Johnson, Michael Oxman, David Patrick, Stéphanie Camden, James A. Mansi. (2010) Predictors of Postherpetic Neuralgia Among Patients With Herpes Zoster: A Prospective Study. The Journal of Pain 11:11, 1211-1221
198
Turna LaNeigh Harkness. (2010) Why Should Older Adults Receive the Shingles Vaccine?. Journal of Gerontological Nursing 36:10, 51-55
199
Katherine J. Bangen, Lisa Delano-Wood, Christina E. Wierenga, Nikki H. Stricker, John R. Hesselink, Mark W. Bondi. (2010) Dementia Following Herpes Zoster Encephalitis. The Clinical Neuropsychologist 24:7, 1193-1203
200
Sinéad Feeney, Eavan Muldoon, Patrick Barrett, Ramon Martos, Niall Mulvihill, Darina O’Flanagan, Colm Bergin. (2010) Varicella infection and the impact of late entry into the Irish healthcare system. Journal of Infection and Public Health 3:3, 106-112
201
V. Manzano, P. Ruiz, M. Torres, F. Gomez. (2010) Severe pneumonia by aciclovir-resistant varicella-zoster virus during etanercept therapy. Rheumatology 49:9, 1791-1793
202
Giorgio Cruccu, Andrea Truini. (2010) Neuropathic pain and its assessment. Surgical Oncology 19:3, 149-154
203
V. Traina-Dorge, B. Pahar, P. Marx, P. Kissinger, D. Montefiori, Y. Ou, W.L. Gray. (2010) Recombinant varicella vaccines induce neutralizing antibodies and cellular immune responses to SIV and reduce viral loads in immunized rhesus macaques. Vaccine 28:39, 6483-6490
204
Kenneth E. Schmader, Gary R. Johnson, Patricia Saddier, Maria Ciarleglio, William W.B. Wang, Jane H. Zhang, Ivan S.F. Chan, Shing-Shing Yeh, Myron J. Levin, Ruth M. Harbecke, Michael N. Oxman, . (2010) Effect of a Zoster Vaccine on Herpes Zoster-Related Interference with Functional Status and Health-Related Quality-of-Life Measures in Older Adults. Journal of the American Geriatrics Society 58:9, 1634-1641
205
Roy Fried. (2010) Zoster Vaccine in Older Adults. Journal of the American Geriatrics Society 58:9, 1799-1800
206
Thomas Weinke, Alexander Edte, Sonja Schmitt, Kati Lukas. (2010) Impact of herpes zoster and post-herpetic neuralgia on patients’ quality of life: a patient-reported outcomes survey. Journal of Public Health 18:4, 367-374
207
Ralf Baron, Andreas Binder, Gunnar Wasner. (2010) Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. The Lancet Neurology 9:8, 807-819
208
Dahlene Fusco, Peter Krawitz, Philip LaRussa, Sharon Steinberg, Anne Gershon, Jonathan Jacobs. (2010) VZV meningitis following varicella vaccine. Journal of Clinical Virology 48:4, 275-277
209
Ana M Bertoli, Graciela S Alarcón. (2010) Perspectives on the management of late-onset systemic lupus erythematosus. Aging Health 6:4, 475-480
210
Karin L. Petersen, Michael C. Rowbotham. (2010) Natural history of sensory function after herpes zoster. PAIN 150:1, 83-92
211
Kumi Ueno-Yamamoto, Keiko Tanaka-Taya, Hiroshi Satoh, Kazuko Araki, Mitsuo Kaku, Nobuhiko Okabe. (2010) THE CHANGING SEROEPIDEMIOLOGY OF VARICELLA IN JAPAN. The Pediatric Infectious Disease Journal 29:7, 667-669
212
L. Salleras, M. Salleras. (2010) Vacunación frente al herpes zóster. Vacunas 11:3, 110-120
213
T. Jelinek. (2010) Impfprävention bei chronischen Erkrankungen. Prävention und Gesundheitsförderung 5:S1, 5-9
214
Vincent Morelli, Erick Calmet, Varalakshmi Jhingade. (2010) Alternative Therapies for Common Dermatologic Disorders, Part 1. Primary Care: Clinics in Office Practice 37:2, 269-283
215
Miriam Wittek, Hans Wilhelm Doerr, Regina Allwinn. (2010) Varizellen und Herpes zoster. Medizinische Klinik 105:6, 399-403
216
James G. Donahue, Burney A. Kieke, Paul M. Gargiullo, Aisha O. Jumaan, Nicholas R. Berger, Jeremy S. McCauley, Edward A. Belongia. (2010) Herpes Zoster and Exposure to the Varicella Zoster Virus in an Era of Varicella Vaccination. American Journal of Public Health 100:6, 1116-1122
217
S.W. Wassilew, P. Wutzler. (2010) Schutz vor Zoster. Prävention und Gesundheitsförderung 5:S1, 23-27
218
Richard Mills, Stephen K. Tyring, Myron J. Levin, Janie Parrino, Xiaoming Li, Kathleen E. Coll, Jon E. Stek, Katia Schlienger, Ivan S.F. Chan, Jeffrey L. Silber. (2010) Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine 28:25, 4204-4209
219
Miriam Wittek, Hans Wilhelm Doerr, Regina Allwinn. (2010) Varizellen und Herpes zoster. Medizinische Klinik 105:5, 334-338
220
Wim Opstelten, Janet McElhaney, Birgit Weinberger, Anne Louise Oaklander, Robert W. Johnson. (2010) The impact of varicella zoster virus: Chronic pain. Journal of Clinical Virology 48, S8-S13
221
Richard J. Whitley, Antonio Volpi, Mike McKendrick, Albert van Wijck, Anne Louise Oaklander. (2010) Management of herpes zoster and post-herpetic neuralgia now and in the future. Journal of Clinical Virology 48, S20-S28
222
A. Gatti, F. Pica, M.T.Y. Boccia, F. De Antoni, A.F. Sabato, A. Volpi. (2010) No evidence of family history as a risk factor for herpes zoster in patients with post-herpetic neuralgia. Journal of Medical Virology 82:6, 1007-1011
223
Myron J. Levin, Anne A. Gershon, Robert H. Dworkin, Marc Brisson, Lawrence Stanberry. (2010) Prevention strategies for herpes zoster and post-herpetic neuralgia. Journal of Clinical Virology 48, S14-S19
224
Hyong Jin Cho, Helen Lavretsky, Richard Olmstead, Myron Levin, Michael N. Oxman, Michael R. Irwin. (2010) Prior Depression History and Deterioration of Physical Health in Community-Dwelling Older Adults—A Prospective Cohort Study. American Journal of Geriatric Psychiatry 18:5, 442-451
225
Marc Brisson, Gurgen Melkonyan, Melanie Drolet, Gaston De Serres, Roseline Thibeault, Philippe De Wals. (2010) Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster. Vaccine 28:19, 3385-3397
226
Won Suk Choi, Ji Yun Noh, Joong Yeon Huh, Yu Mi Jo, Jacob Lee, Joon Young Song, Woo Joo Kim, Hee Jin Cheong. (2010) Disease burden of herpes zoster in Korea. Journal of Clinical Virology 47:4, 325-329
227
Z. GAO, H. F. GIDDING, J. G. WOOD, C. R. MacINTYRE. (2010) Modelling the impact of one-dose vs. two-dose vaccination regimens on the epidemiology of varicella zoster virus in Australia. Epidemiology and Infection 138:04, 457
228
Alexander Ademokun, Yu-Chang Wu, Deborah Dunn-Walters. (2010) The ageing B cell population: Composition and function. Biogerontology 11:2, 125-137
229
Aruna P.N. Ambagala, Tammy Krogmann, Jing Qin, Lesley Pesnicak, Jeffrey I. Cohen. (2010) A varicella-zoster virus mutant impaired for latency in rodents, but not impaired for replication in cell culture. Virology 399:2, 194-200
230
Robert H. Dworkin, Daniel C. Malone, Christopher J. Panarites, Edward P. Armstrong, Sissi V. Pham. (2010) Impact of Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy on Health Care Costs. The Journal of Pain 11:4, 360-368
231
J. Breuer, C. Grose, P. Norberg, G. Tipples, D. S. Schmid. (2010) A proposal for a common nomenclature for viral clades that form the species varicella-zoster virus: summary of VZV Nomenclature Meeting 2008, Barts and the London School of Medicine and Dentistry, 24-25 July 2008. Journal of General Virology 91:4, 821-828
232
L. Salleras, M. Salleras. (2010) Epidemiología del herpes zóster. Vacunas 11:2, 66-73
233
Joel V Chua, Wilbur H Chen. (2010) Herpes zoster vaccine for the elderly: boosting immunity. Aging Health 6:2, 169-176
234
J. C. Sterling. Virus Infections. In: Rook's Textbook of Dermatology. Wiley-Blackwell, 2010:1-81.
235
Jitendra Ganju. Size of Clinical Trials. In: Pharmaceutical Sciences Encyclopedia. John Wiley & Sons, Inc., 2010.
236
Montse Tuset, Ester López-Suñé, Carlos Cervera, Asunción Moreno, José M. Miró. (2010) Características de los fármacos antivíricos frente a virus del grupo herpes actualización 2009. Enfermedades Infecciosas y Microbiología Clínica 28:3, 199.e1-199.e33
237
Robert W Johnson. (2010) Herpes zoster and postherpetic neuralgia. Expert Review of Vaccines 9:3s, 21-26
238
Gérard Mick. (2010) Vaccination: a new option to reduce the burden of herpes zoster. Expert Review of Vaccines 9:3s, 31-35
239
Turo J. Nurmikko. Postherpetic Neuralgia. In: Evidence-Based Chronic Pain Management. Wiley-Blackwell, 2010:222-236.
240
Yung-Hsiu Lin, Li-Min Huang, I-Shou Chang, Fang-Yu Tsai, Chun-Yi Lu, Pei-Lan Shao, Luan-Yin Chang. (2010) Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan. Vaccine 28:5, 1217-1220
241
I. Ridda, C.R. MacIntyre, R.I. Lindley, T.C. Tan. (2010) Difficulties in recruiting older people in clinical trials: An examination of barriers and solutions. Vaccine 28:4, 901-906
242
Justin Bendig, Fiona Sindall. (2010) Chickenpox at Ninety Four: A Case for Extending the Use of Varicella Vaccine in the UK. Case Reports in Medicine 2010, 1-3
243
Mohan K. Tummala, Dennis D. Taub, William B. Ershler. Clinical Immunology. In: Brocklehurst's Textbook of Geriatric Medicine and Gerontology. Elsevier, 2010:82-90.
244
C. B. Archer. . 2010:1.
245
Robin Avery. Adult Immunization. In: Current Clinical Medicine. Elsevier, 2010:796-800.
246
RICHARD J. WHITLEY. Varicella-Zoster Virus. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier, 2010:1963-1969.
247
JEFFREY I. COHEN. Introduction to Herpesviridae. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier, 2010:1937-1942.
248
Larry E. Davis. Infections of the Labyrinth. In: Cummings Otolaryngology - Head and Neck Surgery. Elsevier, 2010:2153-2163.
249
F. Eun-Hyung Lee, John Treanor. Viral Infections. In: Murray and Nadel's Textbook of Respiratory Medicine. Elsevier, 2010:661-698.
250
Sally L. Hodder, Debra Chew, Shobha Swaminathan. Adult Immunization in Women and Men. In: Principles of Gender-Specific Medicine. Elsevier, 2010:563-582.
251
Headache and Facial Pain. In: Clinical Neurology. Elsevier, 2010:168-200.
252
Mike W. McKendrick, Pat Ogan, Chris C. Care. (2009) A 9 year follow up of post herpetic neuralgia and predisposing factors in elderly patients following herpes zoster. Journal of Infection 59:6, 416-420
253
Naruhito Otani, Koichi Baba, Toshiomi Okuno. (2009) Interferon-γ release assay: A simple method for detection of varicella-zoster virus-specific cell-mediated immunity. Journal of Immunological Methods 351:1-2, 71-74
254
Mehdi Najafzadeh, Carlo A. Marra, Eleni Galanis, David M. Patrick. (2009) Cost Effectiveness of Herpes Zoster Vaccine in Canada. PharmacoEconomics 27:12, 991-1004
255
Nozomu Toyama, Kimiyasu Shiraki, . (2009) Epidemiology of herpes zoster and its relationship to varicella in Japan: A 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. Journal of Medical Virology 81:12, 2053-2058
256
Rajbala Thakur, Annie Philip, Jonathan Weeks. Postherpetic Neuralgia. In: Practical Guide to Chronic Pain Syndromes. CRC Press, 2009:30-49.
257
Rachel Civen, Sandra S. Chaves, Aisha Jumaan, Han Wu, Laurene Mascola, Paul Gargiullo, Jane F. Seward. (2009) The Incidence and Clinical Characteristics of Herpes Zoster Among Children and Adolescents After Implementation of Varicella Vaccination. The Pediatric Infectious Disease Journal 28:11, 954-959
258
Genlin Ji, Jiyuan Niu, Yuxiang Shi, Lichao Hou, Yan Lu, Lize Xiong. (2009) The Effectiveness of Repetitive Paravertebral Injections with Local Anesthetics and Steroids for the Prevention of Postherpetic Neuralgia in Patients with Acute Herpes Zoster. Anesthesia & Analgesia 109:5, 1651-1655
259
Catherine Amlie-Lefond, Burk Jubelt. (2009) Neurologic manifestations of varicella zoster virus infections. Current Neurology and Neuroscience Reports 9:6, 430-434
260
Chunbo Li, Jun Xia, Jijun Wang, Chunbo Li. Risperidone dose for schizophrenia. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2009.
261
M. B. Mustafa, P. G. Arduino, S. R. Porter. (2009) Varicella zoster virus: review of its management. Journal of Oral Pathology & Medicine 38:9, 673-688
262
C. McGuigan, J. Balzarini. (2009) FV100 as a new approach for the possible treatment of varicella-zoster virus infection. Journal of Antimicrobial Chemotherapy 64:4, 671-673
263
Marcie Tomblyn, Tom Chiller, Hermann Einsele, Ronald Gress, Kent Sepkowitz, Jan Storek, John R. Wingard, Jo-Anne H. Young, Michael A. Boeckh. (2009) Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective. Biology of Blood and Marrow Transplantation 15:10, 1143-1238
264
(2009) References. Bone Marrow Transplantation 44:8, 537-557
265
Ada Delaney, Lesley A. Colvin, Marie T. Fallon, Robert G. Dalziel, Rory Mitchell, Susan M. Fleetwood-Walker. (2009) Postherpetic neuralgia: From preclinical models to the clinic. Neurotherapeutics 6:4, 630-637
266
L. Salleras, M. Salleras. (2009) Historia natural de la infección por el virus de la varicela zóster. Vacunas 10:4, 125-129
267
S. Márquez-Peláez, J. Ruiz-Aragón. (2009) Revisión sistemática de estudios económicos sobre la vacuna contra herpes zóster y neuralgia postherpética en adultos. Vacunas 10:4, 118-124
268
Alessandro Meduri, Pier Luigi Grenga, Stephen Charles Kaufman. (2009) Herpes zoster ophthalmicus. Expert Review of Ophthalmology 4:5, 537-545
269
R. W. Johnson, J. McElhaney. (2009) Postherpetic neuralgia in the elderly. International Journal of Clinical Practice 63:9, 1386-1391
270
Honorio T. Benzon, Kiran Chekka, Amit Darnule, Brian Chung, Oscar Wille, Khalid Malik. (2009) Evidence-Based Case Report. Regional Anesthesia and Pain Medicine 34:5, 514-521
271
Ronald R. White, Greg Lenhart, Puneet K. Singhal, Ralph P. Insinga, Robbin F. Itzler, James M. Pellissier, Arthur W. Segraves. (2009) Incremental 1-Year Medical Resource Utilization and Costs for Patients with Herpes Zoster from a Set of US Health Plans. PharmacoEconomics 27:9, 781-792
272
Markus Braun-Falco, Marco Hoffmann. (2009) Herpes zoster with progression to acute varicella zoster virus-meningoencephalitis. International Journal of Dermatology 48:8, 834-839
273
Brian E. McGeeney. (2009) Pharmacological Management of Neuropathic Pain in Older Adults: An Update on Peripherally and Centrally Acting Agents. Journal of Pain and Symptom Management 38:2, S15-S27
274
Wolfgang Herr, Bodo Plachter. (2009) Cytomegalovirus and varicella–zoster virus vaccines in hematopoietic stem cell transplantation. Expert Review of Vaccines 8:8, 999-1021
275
Marc E. Weksler, Graham Pawelec, Claudio Franceschi. (2009) Immune therapy for age-related diseases. Trends in Immunology 30:7, 344-350
276
Patricia Bruckenthal, M. Carrington Reid, Lori Reisner. (2009) Special Issues in the Management of Chronic Pain in Older Adults. Pain Medicine 10:S2, S67-S78
277
M. Amparo Torrecilla Rojas, Fermín García Rodríguez, Manuel Rodríguez Rodríguez, Josefa Ruiz Fernández. (2009) La vacunación frente a herpes zóster. Atención Primaria 41:7, 424-425
278
Ruth Harbecke, Michael N. Oxman, Beth A. Arnold, Charlotte Ip, Gary R. Johnson, Myron J. Levin, Lawrence D. Gelb, Kenneth E. Schmader, Stephen E. Straus, Hui Wang, Peter F. Wright, Constance T. Pachucki, Anne A. Gershon, Robert D. Arbeit, Larry E. Davis, Michael S. Simberkoff, Adriana Weinberg, Heather M. Williams, Carol Cheney, Luba Petrukhin, Katalin G. Abraham, Alan Shaw, Susan Manoff, Joseph M. Antonello, Tina Green, Yue Wang, Charles Tan, Paul M. Keller, . (2009) A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses. Journal of Medical Virology 81:7, 1310-1322
279
Wilbur H. Chen, Bernard F. Kozlovsky, Rita B. Effros, Beatrix Grubeck-Loebenstein, Robert Edelman, Marcelo B. Sztein. (2009) Vaccination in the elderly: an immunological perspective. Trends in Immunology 30:7, 351-359
280
Anne A. Gershon, Myron J. Levin, Adriana Weinberg, Lin-Yee Song, Philip S. LaRussa, Sharon P. Steinberg, Patterson Bartlett. (2009) A PHASE I–II STUDY OF LIVE ATTENUATED VARICELLA-ZOSTER VIRUS VACCINE TO BOOST IMMUNITY IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN WITH PREVIOUS VARICELLA. The Pediatric Infectious Disease Journal 28:7, 653-655
281
Irene M. Wielawski. (2009) Shingles and the Vaccine to Prevent It. AJN, American Journal of Nursing 109:6, 63-65
282
Jennifer Turnbull, Lorraine Harper. (2009) Adverse effects of therapy for ANCA-associated vasculitis. Best Practice & Research Clinical Rheumatology 23:3, 391-401
283
Georgios Trimis, Stamatis Gregoriou, Dimos Florakis, Dimitrios Rigopoulos. (2009) Can varicella immunization change the course of herpes zoster while herpes zoster vaccine is underway?. Expert Review of Dermatology 4:3, 219-224
284
Ivan S. F. Chan, William W. B. Wang. (2009) On Analysis of the Difference of Two Exposure-Adjusted Poisson Rates with Stratification: From Asymptotic to Exact Approaches. Statistics in Biosciences 1:1, 65-79
285
Sum Lam, Tomasz Z. Jodlowski. (2009) <b>Vaccines for Older Adults</b>. The Consultant Pharmacist 24:5, 380-391
286
Heidi M. Crane, Shireesha Dhanireddy, H. Nina Kim, Christian Ramers, Timothy H. Dellit, Mari M. Kitahata, Robert D. Harrington. (2009) Optimal timing of routine vaccination in HIV-infected persons. Current HIV/AIDS Reports 6:2, 93-99
287
Janet E McElhaney. (2009) Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response. Expert Review of Vaccines 8:5, 593-606
288
Qifu Li, Ning Chen, Jie Yang, Muke Zhou, Dong Zhou, Quanwei Zhang, Li He, Li He. Antiviral treatment for preventing postherpetic neuralgia. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2009.
289
Robert H. Dworkin, Richard L. Barbano, Stephen K. Tyring, Robert F. Betts, Michael P. McDermott, Janet Pennella-Vaughan, Gary J. Bennett, Erhan Berber, John W. Gnann, Carrie Irvine, Cornelia Kamp, Karl Kieburtz, Mitchell B. Max, Kenneth E. Schmader. (2009) A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain 142:3, 209-217
290
Jean-Pierre Michel, Christian Chidiac, Beatrix Grubeck-Loebenstein, Robert W. Johnson, Paul Henri Lambert, Stefania Maggi, Robert Moulias, Karl Nicholson, Hans Werner. (2009) Advocating Vaccination of Adults Aged 60 Years and Older in Western Europe:. Rejuvenation Research 12:2, 127-136
291
S. Gurunathan, R. El Habib, L. Baglyos, C. Meric, S. Plotkin, B. Dodet, L. Corey, J. Tartaglia. (2009) Use of predictive markers of HIV disease progression in vaccine trials. Vaccine 27:14, 1997-2015
292
Brenda L. Bartlett, Stephen K. Tyring. (2009) Safety and efficacy of vaccines. Dermatologic Therapy 22:2, 97-103
293
Kevin P. High, Suzanne F. Bradley, Stefan Gravenstein, David R. Mehr, Vincent J. Quagliarello, Chesley Richards, Thomas T. Yoshikawa. (2009) Clinical Practice Guideline for the Evaluation of Fever and Infection in Older Adult Residents of Long-Term Care Facilities: 2008 Update by the Infectious Diseases Society of America. Journal of the American Geriatrics Society 57:3, 375-394
294
Rosella Creed, Anita Satyaprakash, Parisa Ravanfar. (2009) Varicella zoster vaccines. Dermatologic Therapy 22:2, 143-149
295
Priya Sampathkumar, Lisa A. Drage, David P. Martin. (2009) Herpes Zoster (Shingles) and Postherpetic Neuralgia. Mayo Clinic Proceedings 84:3, 274-280
296
Esther Grinfeld, Alan Ross, Thorsten Forster, Peter Ghazal, Peter G. E. Kennedy. (2009) Genome-wide reduction in transcriptomal profiles of varicella-zoster virus vaccine strains compared with Parental Oka strain using long oligonucleotide microarrays. Virus Genes 38:1, 19-29
297
Myron J Levin, Jeffrey P Anderson, George R Seage, Paige L Williams. (2009) Short-Term and Long-Term Effects of Highly Active Antiretroviral Therapy on the Incidence of Herpes Zoster in HIV-Infected Children. JAIDS Journal of Acquired Immune Deficiency Syndromes 50:2, 182-191
298
Leonardo Fuks, David Shitrit, Benjamin D. Fox, Anat Amital, Yael Raviv, Ilana Bakal, Mordechai R. Kramer. (2009) Herpes Zoster After Lung Transplantation: Incidence, Timing, and Outcome. The Annals of Thoracic Surgery 87:2, 423-426
299
A.J. van Hoek, N. Gay, A. Melegaro, W. Opstelten, W.J. Edmunds. (2009) Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 27:9, 1454-1467
300
Peng-jun Lu, Gary L. Euler, Aisha O. Jumaan, Rafael Harpaz. (2009) Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: Uptake of the first new vaccine to target seniors. Vaccine 27:6, 882-887
301
Kevin P. High, Suzanne F. Bradley, Stefan Gravenstein, David R. Mehr, Vincent J. Quagliarello, Chesley Richards, Thomas T. Yoshikawa. (2009) Clinical Practice Guideline for the Evaluation of Fever and Infection in Older Adult Residents of Long‐Term Care Facilities: 2008 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases 48:2, 149-171
302
Tetsuo Koshizuka, Yasuko Mori. (2009) The research for development of polyvalent lived vaccine based on current varicella vaccine. Drug Delivery System 24:6, 592-598
303
Miranda A. Farage, Kenneth W. Miller, Enzo Berardesca, Howard I. Maibach. (2009) Clinical Implications of Aging Skin. American Journal of Clinical Dermatology 10:2, 73-86
304
A. GAUTHIER, J. BREUER, D. CARRINGTON, M. MARTIN, V. RÉMY. (2009) Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiology and Infection 137:01, 38
305
Nizar Ajjan. Acquisitions récentes en matière de vaccinations et vaccins du futur. In: La vaccination. Elsevier, 2009:207-301.
306
Yoshizo ASANO. (2009) A live attenuated varicella vaccine. Uirusu 59:2, 249-256
307
Alicia N. Stein, Helena Britt, Christopher Harrison, E. Lynne Conway, Anthony Cunningham, C. Raina MacIntyre. (2009) Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine 27:4, 520-529
308
Mark R. Schleiss. (2009) Persistent and Recurring Viral Infections: The Human Herpesviruses. Current Problems in Pediatric and Adolescent Health Care 39:1, 7-23
309
Paul J. Christo, Brian D. Cauley. POSTHERPETIC NEURALGIA. In: Current Therapy in Pain. Elsevier, 2009:261-267.
310
Wim Opstelten, Gerrit A. van Essen, Eelko Hak. (2009) Determinants of non-compliance with herpes zoster vaccination in the community-dwelling elderly. Vaccine 27:2, 192-196
311
Adaora A. Adimora, David J. Weber. Varicella-Zoster Infections. In: Netter's Internal Medicine. Elsevier, 2009:712-715.
312
S. Porter. Viral and fungal infections of the oral cavity. In: Food constituents and oral health. Woodhead Publishing Limited, 2009:19-50.
313
Paul V. Targonski, Inna G. Ovsyannikova, Pritish K. Tosh, Robert M. Jacobson, Gregory A. Poland. VACCINES. In: Pharmacology and Therapeutics. Elsevier, 2009:1247-1268.
314
Stephanie Studenski, Luigi Ferrucci, Neil M. Resnick. Geriatrics. In: Clinical and Translational Science. Elsevier, 2009:477-495.
315
Russell K. Portenoy, Ricardo Cruciani. Neuropathic Pain. In: Pain Management Secrets. Elsevier, 2009:184-209.
316
Don Gilden, Maria A Nagel, Ravi Mahalingam, Niklaus H Mueller, Elizabeth A Brazeau, Subbiah Pugazhenthi, Randall J Cohrs. (2009) Clinical and molecular aspects of varicella zoster virus infection. Future Neurology 4:1, 103-117
317
Viral Infections. In: Oral and Maxillofacial Pathology. Elsevier, 2009:240-284.
318
Denise D. Wilson. (2008) Herpes Zoster. Advances in Skin & Wound Care 21:12, 582-588
319
Philippe Beutels, Paul A Scuffham, C Raina MacIntyre. (2008) Funding of drugs: do vaccines warrant a different approach?. The Lancet Infectious Diseases 8:11, 727-733
320
Kay Sadaoka, Shigefumi Okamoto, Yasuyuki Gomi, Takeshi Tanimoto, Toyokazu Ishikawa, Tetsushi Yoshikawa, Yoshizo Asano, Koichi Yamanishi, Yasuko Mori. (2008) Measurement of Varicella‐Zoster Virus (VZV)–Specific Cell‐Mediated Immunity: Comparison between VZV Skin Test and Interferon‐γ Enzyme‐Linked Immunospot Assay. The Journal of Infectious Diseases 198:9, 1327-1333
321
AM Geretti, . (2008) British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Medicine 9:10, 795-848
322
Martina Sester, Barbara C. Gärtner, Matthias Girndt, Urban Sester. (2008) Vaccination of the solid organ transplant recipient. Transplantation Reviews 22:4, 274-284
323
Yasuyuki Gomi, Takao Ozaki, Naoko Nishimura, Atsushi Narita, Michio Suzuki, Jaekun Ahn, Naoko Watanabe, Norio Koyama, Hajime Ushida, Naoko Yasuda, Kazumasa Nakane, Keiji Funahashi, Isao Fuke, Akihisa Takamizawa, Toyokazu Ishikawa, Koichi Yamanishi, Michiaki Takahashi. (2008) DNA sequence analysis of varicella-zoster virus gene 62 from subclinical infections in healthy children immunized with the Oka varicella vaccine. Vaccine 26:44, 5627-5632
324
Valentí Pineda, Fernando A. Moraga. (2008) Estado actual de la vacuna de la varicela. Anales de Pediatría Continuada 6:5, 302-306
325
Ravikiran Shenoy, Katherine Roberts, Praveen Anand. Peripheral neuropathies. In: Clinical Pain Management Second Edition. CRC Press, 2008:335-351.
326
Ravikiran Shenoy, Katherine Roberts, Praveen Anand. Peripheral neuropathies. In: Clinical Pain Management Second Edition. CRC Press, 2008:335-351.
327
Lisa A. Jackson, Meredith A. Reynolds, Rafael Harpaz. (2008) Hospitalizations to Treat Herpes Zoster in Older Adults: Causes and Validated Rates. Clinical Infectious Diseases 47:6, 754-759
328
Vasilios German, Georgios Sakagiannis, Georgios Margaritis, Matthew E. Falagas. (2008) Inka Dinka Don't. The American Journal of Medicine 121:9, 772-773
329
A. Volpi, A. Gatti, F. Pica, S. Bellino, L.T. Marsella, A.F. Sabato. (2008) Clinical and psychosocial correlates of post-herpetic neuralgia. Journal of Medical Virology 80:9, 1646-1652
330
M. Najafzadeh, M. Sadatsafavi, C.A. Marra. (2008) Letter to the Editor. Vaccine 26:41, 5244
331
Rita B. Effros, Courtney V. Fletcher, Kelly Gebo, Jeffrey B. Halter, William R. Hazzard, Frances McFarland Horne, Robin E. Huebner, Edward N. Janoff, Amy C. Justice, Daniel Kuritzkes, Susan G. Nayfield, Susan F. Plaeger, Kenneth E. Schmader, John R. Ashworth, Christine Campanelli, Charles P. Clayton, Beth Rada, Nancy F. Woolard, Kevin P. High. (2008) Aging and Infectious Diseases: Workshop on HIV Infection and Aging: What Is Known and Future Research Directions. Clinical Infectious Diseases 47:4, 542-553
332
Stanley A. Plotkin. (2008) Vaccines: Correlates of Vaccine‐Induced Immunity. Clinical Infectious Diseases 47:3, 401-409
333
Marissa B Wilck, Lindsey R Baden. (2008) Vaccination after stem cell transplant: a review of recent developments and implications for current practice. Current Opinion in Infectious Diseases 21:4, 399-408
334
Niklaus H. Mueller, Donald H. Gilden, Randall J. Cohrs, Ravi Mahalingam, Maria A. Nagel. (2008) Varicella Zoster Virus Infection: Clinical Features, Molecular Pathogenesis of Disease, and Latency. Neurologic Clinics 26:3, 675-697
335
Seok Jin Kim, Kihyun Kim, Byung Soo Kim, Hyo-Jin Lee, Hawk Kim, Na-Ri Lee, Seung-Hyun Nam, Jung Hye Kwon, Hyo Jung Kim, Sang Kyun Sohn, Jong-Ho Won, Jae Hoon Lee, Cheolwon Suh, Sung-Soo Yoon, Hye Jin Kim, Inho Kim, Young-Rok Do, Won-Sik Lee, Young-Don Joo, Ho Jin Shin. (2008) Bortezomib and the Increased Incidence of Herpes Zoster in Patients with Multiple Myeloma. Clinical Lymphoma and Myeloma 8:4, 237-240
336
Kristine Macartney, Peter McIntyre, Kristine Macartney. Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2008.
337
Suzanna LR McDonald, Judith Breuer. Varicella Zoster: Virus and Disease. In: Encyclopedia of Life Sciences. John Wiley & Sons, Ltd, 2008.
338
Miriam Wittek. (2008) Fortschritte in der Diagnostik von Varizella Zoster und Stellenwert der Impfung / Advances in varicella zoster virus diagnostics and importance of vaccination. LaboratoriumsMedizin 32:4, 266-273
339
Ted Cohen, Marc Lipsitch. (2008) Too Little of a Good Thing. Epidemiology 19:4, 588-589
340
Miriam Wittek. (2008) Advances in the diagnostics of Varizella zoster virus and importance of vaccination 1. LaboratoriumsMedizin 32:4, ---
341
William P. Carter, Carl A. Germann, Michael R. Baumann. (2008) Ophthalmic diagnoses in the ED: herpes zoster ophthalmicus. The American Journal of Emergency Medicine 26:5, 612-617
342
Adolfo C Fernandez-Obregon, Dhrumil Shah, Amanda I Howell, Imane Tiyal Bentahar, Lester Carrodeguas, Arifa Siddiqui, Julia A Ejiogu. (2008) Challenges in anti-infective therapy for skin conditions: part 1. Expert Review of Dermatology 3:3, 367-394
343
T. Glück, U. Müller‐Ladner. (2008) Vaccines: Vaccination in Patients with Chronic Rheumatic or Autoimmune Diseases. Clinical Infectious Diseases 46:9, 1459-1465
344
Rafael Benoliel, Eli Eliav. (2008) Neuropathic Orofacial Pain. Oral and Maxillofacial Surgery Clinics of North America 20:2, 237-254
345
Kelly K. Curtis, Megan K. Connolly, Donald W. Northfelt. (2008) Live, Attenuated Varicella Zoster Vaccination of an Immunocompromised Patient. Journal of General Internal Medicine 23:5, 648-649
346
James Norman, Douglas Politz. (2008) Shingles (Varicella Zoster) Outbreaks in Patients with Hyperparathyroidism and Their Relationship to Hypercalcemia. Clinical Infectious Diseases 46:9, 1452-1454
347
Warren R. Heymann. (2008) The herpes zoster vaccine. Journal of the American Academy of Dermatology 58:5, 872-873
348
M. Labetoulle. (2008) Le zona ophtalmique. Journal Français d'Ophtalmologie 31:5, 561-562
349
Eva López, Antònia Agustí. (2008) Prevención de la neuralgia postherpética. Medicina Clínica 130:20, 794-796
350
Rajesh Kumar, Edith A Burns. (2008) Age-related decline in immunity: implications for vaccine responsiveness. Expert Review of Vaccines 7:4, 467-479
351
Robert H. Dworkin, Richard White, Alec B. O’Connor, Kevin Hawkins. (2008) Health Care Expenditure Burden of Persisting Herpes Zoster Pain. Pain Medicine 9:3, 348-353
352
Ramón San Miguel, Ana María López-González, Eduardo Sanchez-Iriso, Javier Mar, Juan M. Cabasés. (2008) Measuring health-related quality of life in drug clinical trials: is it given due importance?. Pharmacy World & Science 30:2, 154-160
353
Giuseppina Candore, Carmela Rita Balistreri, Giuseppina Colonna-Romano, Maria Paola Grimaldi, Domenico Lio, Florinda Listi', Letizia Scola, Sonya Vasto, Calogero Caruso. (2008) Immunosenescence and Anti-Immunosenescence Therapies: The Case of Probiotics. Rejuvenation Research 11:2, 425-432
354
Birgit Weinberger, Dietmar Herndler‐Brandstetter, Angelika Schwanninger, Daniela Weiskopf, Beatrix Grubeck‐Loebenstein. (2008) Biology of Immune Responses to Vaccines in Elderly Persons. Clinical Infectious Diseases 46:7, 1078-1084
355
M. J. Levin, M. N. Oxman, J. H. Zhang, G. R. Johnson, H. Stanley, A. R. Hayward, M. J. Caulfield, M. R. Irwin, J. G. Smith, J. Clair, I. S. F. Chan, H. Williams, R. Harbecke, R. Marchese, S. E. Straus, A. Gershon, A. Weinberg, . (2008) Varicella‐Zoster Virus–Specific Immune Responses in Elderly Recipients of a Herpes Zoster Vaccine. The Journal of Infectious Diseases 197:6, 825-835
356
Anne A. Gershon, Samuel L. Katz. (2008) Perspective on Live Varicella Vaccine. The Journal of Infectious Diseases 197:s2, S242-S245
357
Kenneth Schmader, John W. Gnann, Jr., C. Peter Watson. (2008) The Epidemiological, Clinical, and Pathological Rationale for the Herpes Zoster Vaccine. The Journal of Infectious Diseases 197:s2, S207-S215
358
Judith Breuer. (2008) Herpes Zoster: New Insights Provide an Important Wake‐Up Call for Management of Nosocomial Transmission. The Journal of Infectious Diseases 197:5, 635-637
359
Michael N. Oxman, Myron J. Levin, . (2008) Vaccination against Herpes Zoster and Postherpetic Neuralgia. The Journal of Infectious Diseases 197:s2, S228-S236
360
Jeffrey I. Cohen. (2008) Strategies for Herpes Zoster Vaccination of Immunocompromised Patients. The Journal of Infectious Diseases 197:s2, S237-S241
361
Sophie Hambleton, Sharon P. Steinberg, Philip S. LaRussa, Eugene D. Shapiro, Anne A. Gershon. (2008) Risk of Herpes Zoster in Adults Immunized with Varicella Vaccine. The Journal of Infectious Diseases 197:s2, S196-S199
362
Bruce H Thiers. (2008) What's new in dermatologic therapy. Dermatologic Therapy 21:2, 142-149
363
Christine Orlova Urman, Alice B. Gottlieb. (2008) New viral vaccines for dermatologic disease. Journal of the American Academy of Dermatology 58:3, 361-370
364
Laura P. Hurley, Rafael Harpaz, Matthew F. Daley, Lori A. Crane, Brenda L. Beaty, Jennifer Barrow, Christine Babbel, Mona Marin, John F. Steiner, Arthur Davidson, L. Miriam Dickinson, Allison Kempe. (2008) National Survey of Primary Care Physicians Regarding Herpes Zoster and the Herpes Zoster Vaccine. The Journal of Infectious Diseases 197:s2, S216-S223
365
Meredith A. Reynolds, Sandra S. Chaves, Rafael Harpaz, Adriana S. Lopez, Jane F. Seward. (2008) The Impact of the Varicella Vaccination Program on Herpes Zoster Epidemiology in the United States: A Review. The Journal of Infectious Diseases 197:s2, S224-S227
366
Michael R. Irwin. (2008) Human psychoneuroimmunology: 20 Years of discovery. Brain, Behavior, and Immunity 22:2, 129-139
367
Oriol Manuel, Deepali Kumar, Lianne G. Singer, Isabel Cobos, Atul Humar. (2008) Incidence and Clinical Characteristics of Herpes Zoster After Lung Transplantation. The Journal of Heart and Lung Transplantation 27:1, 11-16
368
Koichi Yamanishi. (2008) Perspective for vaccine against infectious diseases. Drug Delivery System 23:2, 151-158
369
Tracy A Lieu, Ismael Ortega-Sanchez, G Thomas Ray, Donna Rusinak, W Katherine Yih, Peter W Choo, Irene Shui, Ken Kleinman, Rafael Harpaz, Lisa A Prosser. (2008) Community and Patient Values for Preventing Herpes Zoster. PharmacoEconomics 26:3, 235-249
370
Adnan Said, Nasia Safdar, Jennifer Wells, Michael R. Lucey. Liver Disease in Renal Transplant Recipients. In: Kidney Transplantation. Elsevier, 2008:508-533.
371
Woo Seok Sim, Jin Hwan Choi, Kyung Ream Han, Yong Chul Kim. (2008) Treatment of Herpes Zoster and Postherpetic Neuralgia. The Korean Journal of Pain 21:2, 93
372
A. A. Gershon. (2008) Varicella-Zoster Virus Infections. Pediatrics in Review 29:1, 5-11
373
A. Serrie, V. Mourman, M.-H. Toussaint, C. Thurel. (2008) Algie craniofacciali. EMC - Otorinolaringoiatria 7:2, 1-15
374
Elon Eisenberg. (2008) European Pain Management Discussion Forum. Journal of Pain and Palliative Care Pharmacotherapy 22:3, 235-238
375
Robert W Johnson, Gunnar Wasner, Patricia Saddier, Ralf Baron. (2008) Herpes Zoster and Postherpetic Neuralgia. Drugs & Aging 25:12, 991-1006
376
W. Lawrence Drew, Kim S. Erlich. Management of Herpesvirus Infections (Cytomegalovirus, Herpes Simplex Virus, and Varicella-Zoster Virus). In: Global HIV/AIDS Medicine. Elsevier, 2008:437-461.
377
R. K. Avery, M. Michaels. (2008) Update on Immunizations in Solid Organ Transplant Recipients: What Clinicians Need to Know. American Journal of Transplantation 8:1, 9-14
378
Marylou V. Solbrig, Kenneth L. Tyler. Infections of the Nervous System. In: Neurology in Clinical Practice. Elsevier, 2008:1457-1488.
379
Luis Salleras Sanmartí, Monserrat Salleras Redonnet, Andrés Prat, Patricio Garrido, Ángela Domínguez. (2008) Vacunas frente al virus de la varicela zóster. Enfermedades Infecciosas y Microbiología Clínica 26, 29-47
380
Kayode A. Williams, Robert W. Hurley, Elaina E. Lin, Christopher L. Wu. Neuropathic Pain Syndromes. In: Raj's Practical Management of Pain. Elsevier, 2008:427-443.
381
Karen D. Sims, Emily A. Blumberg. Prevention and Treatment of Infection in Kidney Transplant Recipients. In: Therapy in Nephrology & Hypertension. Elsevier, 2008:1034-1046.
382
A. Serrie, V. Mourman, M.-H. Toussaint, C. Thurel. (2008) Algias craneofaciales. EMC - Otorrinolaringología 37:2, 1-16
383
A. Serrie, V. Mourman, M.-H. Toussaint, C. Thurel. (2008) Algies craniofaciales. EMC - Oto-rhino-laryngologie 3:1, 1-15
384
Kathryn N. Suh. Elderly. In: Travel Medicine. Elsevier, 2008:235-241.
385
Ivan S. F. Chan. Vaccine. In: Wiley Encyclopedia of Clinical Trials. John Wiley & Sons, Inc., 2007.
386
M. Brisson, J. M. Pellissier, M. J. Levin. (2007) Cost-Effectiveness of Herpes Zoster Vaccine: Flawed Assumptions Regarding Efficacy against Postherpetic Neuralgia. Clinical Infectious Diseases 45:11, 1527-1529
387
Mazen S. Bader. (2007) Immunization for the Elderly. The American Journal of the Medical Sciences 334:6, 481-486
388
Jeffrey M. Weinberg. (2007) Herpes zoster: Epidemiology, natural history, and common complications. Journal of the American Academy of Dermatology 57:6, S130-S135
389
Robert F. Betts. (2007) Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia. Journal of the American Academy of Dermatology 57:6, S143-S147
390
W A Orenstein, G T Mootrey, K Pazol, A R Hinman. (2007) Financing Immunization of Adults in the United States. Clinical Pharmacology & Therapeutics 82:6, 764-768
391
Robert Johnson, Janet McElhaney, Biagio Pedalino, Myron Levin. (2007) Prevention of herpes zoster and its painful and debilitating complications. International Journal of Infectious Diseases 11, S43-S48
392
D. C. Braun, A. C. Birch, D. Benson, R. F. Stein, A. Nordlund. (2007) Helioseismic Holography of Simulated Solar Convection and Prospects for the Detection of Small‐Scale Subsurface Flows. The Astrophysical Journal 669:2, 1395-1405
393
Barbara P. Yawn, Patricia Saddier, Peter C. Wollan, Jennifer L. St. Sauver, Marge J. Kurland, Lina S. Sy. (2007) A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction. Mayo Clinic Proceedings 82:11, 1341-1349
394
Israel Steiner, Peter GE Kennedy, Andrew R Pachner. (2007) The neurotropic herpes viruses: herpes simplex and varicella-zoster. The Lancet Neurology 6:11, 1015-1028
395
James M. Pellissier, Marc Brisson, Myron J. Levin. (2007) Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 25:49, 8326-8337
396
Robert W Johnson, Gunnar Wasner, Patricia Saddier, Ralf Baron. (2007) Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Review of Neurotherapeutics 7:11, 1581-1595
397
Fred J. Friel. (2007) Herpes zoster in 2007: Treatment and prevention. Journal of the American Academy of Physician Assistants 20:11, 21-25
398
Qifu Li, Li He, Quanwei Zhang, Muke Zhou, Dong Zhou, Li He. Antiviral treatment for preventing postherpetic neuralgia. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2007.
399
V. Erard, K. A. Guthrie, C. Varley, J. Heugel, A. Wald, M. E. D. Flowers, L. Corey, M. Boeckh. (2007) One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 110:8, 3071-3077
400
Boris Kerzner, Alexander V. Murray, Eric Cheng, Rudy Ifle, Peter R. Harvey, Mark Tomlinson, Julie L. Barben, Kimberly Rarrick, Jon E. Stek, Mi-Ok Chung, Florian P. Schödel, William W. B. Wang, Jin Xu, Ivan S. F. Chan, Jeffrey L. Silber, Katia Schlienger. (2007) Safety and Immunogenicity Profile of the Concomitant Administration of ZOSTAVAX and Inactivated Influenza Vaccine in Adults Aged 50 and Older. Journal of the American Geriatrics Society 55:10, 1499-1507
401
Lily N. Clark, Mark Lebwohl. (2007) Recent advances in medical dermatology. International Journal of Dermatology 46:10, 1005-1010
402
Julie Patterson-Bartlett, Myron J. Levin, Nancy Lang, Florian P. Schödel, Rupert Vessey, Adriana Weinberg. (2007) Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine 25:41, 7087-7093
403
Yi-Wei Tang, Hatim T. Allawi, Marlene DeLeon-Carnes, Haijing Li, Stephen P. Day, D. Scott Schmid. (2007) Detection and differentiation of wild-type and vaccine mutant varicella-zoster viruses using an Invader Plus® method. Journal of Clinical Virology 40:2, 129-134
404
Alexander Doroshenko, Scott A Halperin. (2007) Vaccination: the importance of herd immunity. Pediatric Health 1:1, 35-42
405
Mark D. Pescovitz. (2007) Antiviral Therapies for Cytomegalovirus in Solid-Organ Transplantation. Transplantation 84:Supplement, S2-S6
406
Paul J. Drinka. (2007) How Should Nursing Homes Use Vaccine to Prevent Zoster?. Journal of the American Medical Directors Association 8:7, 419-420
407
Tin Han Htwe, Adnan Mushtaq, Sherry B. Robinson, Richard B. Rosher, Nancy Khardori. (2007) Infection in the Elderly. Infectious Disease Clinics of North America 21:3, 711-743
408
Camille Nelson Kotton. (2007) Nailing down the shingles in IBD. Inflammatory Bowel Diseases 13:9, 1178-1179
409
Yang Ou, Vicki Traina-Dorge, Kara A. Davis, Wayne L. Gray. (2007) Recombinant simian varicella viruses induce immune responses to simian immunodeficiency virus (SIV) antigens in immunized vervet monkeys. Virology 364:2, 291-300
410
A. A. GERSHON. (2007) Vaccination to prevent zoster in the elderly. Epidemiology and Infection 135:06, 883
411
Eun Jeong Kwak, Robin K Avery. (2007) Strategies for the prevention of infectious complications after renal transplantation. Current Opinion in Organ Transplantation 12:4, 362-370
412
Robert H. Dworkin, Richard White, Alec B. O'Connor, Onur Baser, Kevin Hawkins. (2007) Healthcare Costs of Acute and Chronic Pain Associated with a Diagnosis of Herpes Zoster. Journal of the American Geriatrics Society 55:8, 1168-1175
413
Gerd Gros, Hans‐Wilhelm Doerr, Maria Grazia Revello. (2007) Herpes Zoster: Recent Aspects of Diagnosis and Control:Herpes Zoster: Recent Aspects of Diagnosis and Control. Clinical Infectious Diseases 45:3, 408-408
414
Kenneth Schmader. (2007) Herpes Zoster and Postherpetic Neuralgia in Older Adults. Clinics in Geriatric Medicine 23:3, 615-632
415
Edgar Turner Overton. (2007) An overview of vaccinations in HIV. Current HIV/AIDS Reports 4:3, 105-113
416
Kedar Adour. Epstein-Barr, Herpes Simplex and Herpes Zoster Infections. In: Head and Neck Manifestations of Systemic Disease. CRC Press, 2007:125-144.
417
(2007) Varicella–Zoster Vaccine. New England Journal of Medicine 357:1, 88-90
Free Full Text418
Timo Vesikari, Catherine Sadzot-Delvaux, Bernard Rentier, Anne Gershon. (2007) Increasing Coverage and Efficiency of Measles, Mumps, and Rubella Vaccine and Introducing Universal Varicella Vaccination in Europe. The Pediatric Infectious Disease Journal 26:7, 632-638
419
Kenneth E. Schmader, Richard Sloane, Carl Pieper, Paul M. Coplan, Alexander Nikas, Patricia Saddier, Ivan S. F. Chan, Peter Choo, Myron J. Levin, Gary Johnson, Heather M. Williams, Michael N. Oxman. (2007) The Impact of Acute Herpes Zoster Pain and Discomfort on Functional Status and Quality of Life in Older Adults. The Clinical Journal of Pain 23:6, 490-496
420
Kimberly A. Cappuzzo, René Roberts Krogsund. (2007) <b>Postherpetic Neuralgia in an Elderly Patient</b>. The Consultant Pharmacist 22:7, 593-598
421
Denise R Kockler, Michelle W McCarthy. (2007) Zoster Vaccine Live. Pharmacotherapy 27:7, 1013-1019
422
Rachel Espiritu, Michael Rich. (2007) Herpes Zoster Encephalitis. Infectious Diseases in Clinical Practice 15:4, 284-288
423
KATIE IVERSON. (2007) Q: Should I get the shingles vaccine?. Journal of the American Academy of Physician Assistants 20:7, 55
424
Birger Trollfors. (2007) General vaccination of children against varicella?-Yes!. Acta Paediatrica 96:6, 794-795
425
Gary Laustsen, Tim Neilson. (2007) Prevent Shingles with Zostavax. The Nurse Practitioner 32:6, 6-7
426
M. B. Rothberg, A. Virapongse, K. J. Smith. (2007) Cost-Effectiveness of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. Clinical Infectious Diseases 44:10, 1280-1288
427
Alan E. Simon, Albert W. Wu, Philip W. Lavori, Jeremy Sugarman. (2007) Preventive Misconception. American Journal of Preventive Medicine 32:5, 370-374
428
Juan Jorge Manriquez, Maria Francisca Villouta, Hywel C. Williams. (2007) Evidence-based dermatology: Number needed to treat and its relation to other risk measures. Journal of the American Academy of Dermatology 56:4, 664-671
429
Caren McHenry Martin, Lauri G. Saleeby. (2007) <b>All Pain Is Not the Same: An Overview of Neuropathic Pain in the Elderly</b>. The Consultant Pharmacist 22:4, 283-294
430
G. G. Miller, J. S. Dummer. (2007) Herpes Simplex and Varicella Zoster Viruses: Forgotten but Not Gone. American Journal of Transplantation 7:4, 741-747
431
Antonio Volpi, Antonio Gatti, Giuseppe Serafini, Bruno Costa, Barbara Suligoi, Francesca Pica, Luigi T. Marsella, Elisabetta Sabato, Alessandro F. Sabato. (2007) Clinical and psychosocial correlates of acute pain in herpes zoster. Journal of Clinical Virology 38:4, 275-279
432
Po-yuan Wu, Yu-Chuan Li, Hong-Dar Isaac Wu. (2007) Risk factors for chickenpox incidence in Taiwan from a large-scale computerized database. International Journal of Dermatology 46:4, 362-366
433
Alexandra Y. Zhang, Craig A. Elmets, William L. Camp, Boni E. Elewski. (2007) New opportunities in preventative dermatology: How far should we go?. Journal of the American Academy of Dermatology 56:4, 675-676
434
Michael R. Irwin, Richard Olmstead, Michael N. Oxman. (2007) Augmenting Immune Responses to Varicella Zoster Virus in Older Adults: A Randomized, Controlled Trial of Tai Chi. Journal of the American Geriatrics Society 55:4, 511-517
435
Hassan Vally, Gary K. Dowse, Keith Eastwood, Scott Cameron. (2007) An outbreak of chickenpox at a child care centre in Western Australia. Costs to the community and implications for vaccination policy. Australian and New Zealand Journal of Public Health 31:2, 113-119
436
Janne Ludwig, Ralf Baron. (2007) Prevention and treatment of postherpetic neuralgia. Aging Health 3:2, 223-230
437
Kimberlin , David W. , Whitley , Richard J. , . (2007) Varicella–Zoster Vaccine for the Prevention of Herpes Zoster. New England Journal of Medicine 356:13, 1338-1343
Full Text438
Michael A.O. Lewis, Vidya Sankar, Antoon De Laat, Rafael Benoliel. (2007) Management of neuropathic orofacial pain. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 103, S32.e1-S32.e24
439
Robert W. Johnson, Andrew S.C. Rice. (2007) Pain following herpes zoster: The influence of changing population characteristics and medical developments. Pain 128:1-2, 3-5
440
N. Macaladad, T. Marcano, M. Guzman, J. Moya, F. Jurado, M. Thompson, C. Meechan, D. Li, K. Schlienger, I. Chan, J. Sadoff, F. Schödel, J.L. Silber. (2007) Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Vaccine 25:11, 2139-2144
441
Ian Gilron, Terence J Coderre. (2007) Emerging drugs in neuropathic pain. Expert Opinion on Emerging Drugs 12:1, 113-126
442
Tamas Fülöp, Anis Larbi, Katsuiku Hirokawa, Eugenio Mocchegiani, Bruno Lesourd, Stephen Castle, Anders Wikby, Claudio Franceschi, Graham Pawelec. (2007) Immunosupportive therapies in aging. Clinical Interventions in Aging 2:1, 33-54
443
Karin L. Petersen, Hans Gustav Thyregod, Michael C. Rowbotham. (2007) Response to the Letter to the Editor by Robert Dworkin. Pain 128:1-2, 190-192
444
Robert H. Dworkin. (2007) Inadequate evidence for a revised definition of postherpetic neuralgia (PHN). Pain 128:1-2, 189-190
445
Hans Gustav Thyregod, Michael C. Rowbotham, Michelle Peters, Jessica Possehn, Marlene Berro, Karin Lottrup Petersen. (2007) Natural history of pain following herpes zoster. Pain 128:1-2, 148-156
446
Stephen K. Tyring, Francisco Diaz-Mitoma, Larry G. Padget, Margarita Nunez, Gregory Poland, William M. Cassidy, Nickoya D. Bundick, Jianjun Li, Ivan S.F. Chan, Jon E. Stek, Paula W. Annunziato. (2007) Safety and tolerability of a high-potency zoster vaccine in adults ≥50 years of age. Vaccine 25:10, 1877-1883
447
Donald H Gilden, Ravi Mahalingam, Randall J Cohrs, Kenneth L Tyler. (2007) Herpesvirus infections of the nervous system. Nature Clinical Practice Neurology 3:2, 82-94
448
Rachel Spieldoch, Libby Edwards. Vulvovaginal Infections. In: Vulvar Disease. CRC Press, 2007:67-107.
449
J.A. Stockman. (2007) A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. Yearbook of Pediatrics 2007, 31-33
450
Paul J Christo, Greg Hobelmann, David N Maine. (2007) Post-Herpetic Neuralgia in Older Adults. Drugs & Aging 24:1, 1-19
451
Elaina G. Lindberg. (2007) Is There a Role for Herpes Zoster Vaccine in Chronic Pain Management?. Journal of Pain and Palliative Care Pharmacotherapy 21:3, 99-100
452
Rita B. Effros. (2007) Role of T lymphocyte replicative senescence in vaccine efficacy. Vaccine 25:4, 599-604
453
R. H. Dworkin, R. W. Johnson, J. Breuer, J. W. Gnann, M. J. Levin, M. Backonja, R. F. Betts, A. A. Gershon, M. L. Haanpaa, M. W. McKendrick, T. J. Nurmikko, A. L. Oaklander, M. N. Oxman, D. P. Langston, K. L. Petersen, M. C. Rowbotham, K. E. Schmader, B. R. Stacey, S. K. Tyring, A. J. M. v. Wijck, M. S. Wallace, S. W. Wassilew, R. J. Whitley. (2007) Recommendations for the Management of Herpes Zoster. Clinical Infectious Diseases 44:Supplement 1, S1-S26
454
Michael M Lederman, Adam Penn-Nicholson, Shelley F Stone, Scott F Sieg, Benigno Rodriguez. (2007) Monitoring clinical trials of therapeutic vaccines in HIV infection: role of treatment interruption. Current Opinion in HIV and AIDS 2:1, 56-61
455
Ralph P Insinga, Robbin F Itzler, James M Pellissier. (2007) Acute/Subacute Herpes Zoster. PharmacoEconomics 25:2, 155-169
456
Tony S. Ma, Tracie C. Collins, Gabriel Habib, Audrius Bredikis, Blase A. Carabello. (2007) Herpes Zoster and Its Cardiovascular Complications in the Elderly – Another Look at a Dormant Virus. Cardiology 107:1, 63-67
457
Thomas Hadjistavropoulos, Keela Herr, Dennis C. Turk, Perry G. Fine, Robert H. Dworkin, Robert Helme, Kenneth Jackson, Patricia A. Parmelee, Thomas E. Rudy, B. Lynn Beattie, John T. Chibnall, Kenneth D. Craig, Betty Ferrell, Bruce Ferrell, Roger B. Fillingim, Lucia Gagliese, Romayne Gallagher, Stephen J. Gibson, Elizabeth L. Harrison, Benny Katz, Francis J. Keefe, Susan J. Lieber, David Lussier, Kenneth E. Schmader, Raymond C. Tait, Debra K. Weiner, Jaime Williams. (2007) An Interdisciplinary Expert Consensus Statement on Assessment of Pain in Older Persons. The Clinical Journal of Pain 23:Supplement 1, S1-S43
458
Sashank Prasad, Steven Galetta. The Trigeminal Nerve. In: Textbook of Clinical Neurology. Elsevier, 2007:165-183.
459
Misha-Miroslav Backonja. Postherpetic neuralgia. In: Neurobiology of Disease. Elsevier, 2007:1031-1037.
460
B. Salzberger. (2006) Antivirale Therapie. Der Internist 47:12, 1245-1250
461
Wim Opstelten. (2006) Herpes zoster: geen roos zonder doorn. Huisarts en Wetenschap 49:12, 863-868
462
Lesley Ann Saketkoo, Luis R. Espinoza. (2006) Impact of Biologic Agents on Infectious Diseases. Infectious Disease Clinics of North America 20:4, 931-961
463
Gauree Gupta, Ebbing Lautenbach, James D. Lewis. (2006) Incidence and Risk Factors for Herpes Zoster Among Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 4:12, 1483-1490
464
Siobhan L West, Richard W Newton, Eileen M Baildam, Andrew J Turner, Peter D Arkwright. (2006) Recurrent hemiplegia associated with cerebral vasculopathy following third trimester maternal herpes zoster infection. Developmental Medicine & Child Neurology 48:12, 991-993
465
John J. Docherty, Thomas J. Sweet, Erin Bailey, Seth A. Faith, Tristan Booth. (2006) Resveratrol inhibition of varicella-zoster virus replication in vitro. Antiviral Research 72:3, 171-177
466
Clemente Diaz, Pietro Dentico, Rocio Gonzalez, Rafael G. Mendez, Sandro Cinquetti, Julie L. Barben, Anna Harmon, Ira Chalikonda, Jeffrey G. Smith, Jon E. Stek, Andrew Robertson, Michael J. Caulfield, Luigi R. Biasio, Jeffrey L. Silber, Christina Y. Chan, Rupert Vessey, Jerald Sadoff, Ivan S.F. Chan, Holly Matthews, William Wang, Katia Schlienger, Florian P. Schödel. (2006) Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects ≥13 years of age. Vaccine 24:47-48, 6875-6885
467
Nicholas Wood, Peter McIntyre, Melanie Wong. (2006) Vaccination for the paediatrician. Journal of Paediatrics and Child Health 42:11, 665-673
468
Ulrich Heininger, Jane F Seward. (2006) Varicella. The Lancet 368:9544, 1365-1376
469
Sawko W. Wassilew. (2006) Zoster-associated neuralgias. JDDG 4:10, 871-881
470
Kenneth E. Schmader, Jack Twersky. Herpes Zoster, Cellulitis, and Scabies. Informa Healthcare, 2006:277-296.
471
Michael D. Hogue, Robert D. Arbeit, Lawrence D. Gelb. (2006) Reducing the Burden of Herpes Zoster and Postherpetic Neuralgia Through Vaccination. The Consultant Pharmacist 21:0, 1-24
472
Rex Biedenbender, Stefan Gravenstein, Arvydas Ambrozaitis. Vaccinations. Informa Healthcare, 2006:369-390.
473
Hein J. Boot, Hester E. de Melker, Elly A. Stolk, G. Ardine de Wit, Tjeerd G. Kimman. (2006) Assessing the introduction of universal varicella vaccination in the Netherlands. Vaccine 24:37-39, 6288-6299
474
Sarosh J. Motivala, Myron J. Levin, Michael N. Oxman, Michael R. Irwin. (2006) Impairments in Health Functioning and Sleep Quality in Older Adults with a History of Depression. Journal of the American Geriatrics Society 54:8, 1184-1191
475
Pamela P. W. Lee, Tze-Leung Lee, Marco Hok-Kung Ho, Wilfred H. S. Wong, Yu-Lung Lau. (2006) Herpes Zoster in Juvenile-Onset Systemic Lupus Erythematosus. The Pediatric Infectious Disease Journal 25:8, 728-732
476
Lyn C Guenther. (2006) Herpes zoster and postherpetic neuralgia. Expert Review of Dermatology 1:4, 607-618
477
Mark Holodniy. (2006) Prevention of shingles by varicella zoster virus vaccination. Expert Review of Vaccines 5:4, 431-443
478
Wolf Nurnberg, Burkhard Schneeweiss. (2006) Varicella vaccination update Neuere Erkenntnisse zur Varizellenimpfung. JDDG 4:7, 540-543
479
Dwight Moulin. (2006) Does acute pain associated with herpes zoster respond to treatment with gabapentin?. Nature Clinical Practice Neurology 2:6, 298-299
480
David E. Michalik, Anne A. Gershon. (2006) Zoster vaccine for the elderly. Drug Discovery Today: Therapeutic Strategies 3:2, 237-241
481
Hester de Melker, Guy Berbers, Susan Hahné, Hans Rümke, Susan van den Hof, Ardine de Wit, Hein Boot. (2006) The epidemiology of varicella and herpes zoster in The Netherlands: Implications for varicella zoster virus vaccination. Vaccine 24:18, 3946-3952
482
Velio Alvaro Bocci. (2006) Scientific and Medical Aspects of Ozone Therapy. State of the Art. Archives of Medical Research 37:4, 425-435
483
Alan R. Hinman, Walter A. Orenstein, Jeanne M. Santoli, Lance E. Rodewald, Stephen L. Cochi. (2006) VACCINE SHORTAGES: History, Impact, and Prospects for the Future*. Annual Review of Public Health 27:1, 235-259
484
Matthew M Davis. (2006) Successes and remaining challenges after 10 years of varicella vaccination in the USA. Expert Review of Vaccines 5:2, 295-302
485
B. T. Rouse, S. D. Kaistha. (2006) A Tale of Two -Herpesviruses: Lessons for Vaccinologists. Clinical Infectious Diseases 42:6, 810-817
486
Dietmar Herndler-Brandstetter, Daniel P. Cioca, Beatrix Grubeck-Loebenstein. (2006) Immunizations in the elderly: do they live up to their promise?. Wiener Medizinische Wochenschrift 156:5-6, 130-141
487
A. Weinberg, S.P. Horslen, S.S. Kaufman, R. Jesser, A. DeVoll-Zabrocki, B.L. Fleckten, S. Kochanowicz, K.R. Seipel, M.J. Levin. (2006) Safety and Immunogenicity of Varicella-Zoster Virus Vaccine in Pediatric Liver and Intestine Transplant Recipients. American Journal of Transplantation 6:3, 565-568
488
Todd D. Gleeson, Mark R. Wallace, Sybil A. Tasker. (2006) Vaccination in patients with HIV infection. Current Infectious Disease Reports 8:2, 151-161
489
Sharon Gatewood, Jean-Venable R. Goode, Dennis Stanley. (2006) Keeping Up-to-Date on Immunizations: A Framework and Review for Pharmacists. Journal of the American Pharmacists Association 46:2, 183-192
490
&NA;. (2006) Evaluation Form: Pediatric Infectious Disease Journal?? Supplement: Advances in Prevention of Cervical Cancer and Other Human Papillomavirus-Related Diseases. The Pediatric Infectious Disease Journal 25:Supplement, S83-S84
491
Judith L. Beizer, Edward H. Davidson. (2006) Journal Review. The Consultant Pharmacist 21:2, 147-150
492
Ann M. Arvin, Harry B. Greenberg. (2006) New viral vaccines. Virology 344:1, 240-249
493
B THIERS. (2006) A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsOxman MN, for the Shingles Prevention Study Group (VA San Diego Healthcare System, Calif; et al) N Engl J Med 352:2271–2284, 2005§. Yearbook of Dermatology and Dermatologic Surgery 2006, 134-135
494
B THIERS. (2006) Decline in Mortality Due to Varicella After Implementation of Varicella Vaccination in the United StatesNguyen HQ, Jumaan AO, Seward JF (Ctrs for Disease Control and Prevention, Atlanta, Ga) N Engl J Med 352:450–458, 2005§. Yearbook of Dermatology and Dermatologic Surgery 2006, 135-136
495
E COHEN. (2006) A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsOxman MN, for the Shingles Prevention Study Group (VA San Diego Healthcare System, Calif; et al) N Engl J Med 352:2271–2284, 2005§. Yearbook of Ophthalmology 2006, 264-269
496
D SNYDMAN. (2006) A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsOxman MN, for the Shingles Prevention Study Group (VA San Diego Healthcare System, Calif; et al) N Engl J Med 352:2271–2284, 2005§. Yearbook of Medicine 2006, 117-118
497
Jan Bonhoeffer, Paul T. Heath, E. Graham Davies, Deirdre A. Kelly, David C. Wilson. (2006) Update on new vaccines and immunisation strategies. Current Paediatrics 16:1, 1
498
Larry E Davis. (2006) Neurological infections: clinical advances, global threats. The Lancet Neurology 5:1, 7-8
499
A VERMA. (2006) A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsOxman MN, for the Shingles Prevention Study Group (VA San Diego Healthcare System, Calif; et al) N Engl J Med 352:2271–2284, 2005§. Yearbook of Neurology and Neurosurgery 2006, 104-106
500
C. Peter N. Watson, Anne Louise Oaklander. Chapter 44 Postherpetic neuralgia. Elsevier, 2006:661-677.
501
Arturo Casadevall, Liise‐anne Pirofski. A Reappraisal of Humoral Immunity Based on Mechanisms of Antibody‐Mediated Protection Against Intracellular Pathogens. Elsevier, 2006:1-44.
502
Peter K. Wung, Janet T. Holbrook, Gary S. Hoffman, Andrea K. Tibbs, Ulrich Specks, Y.-I. Min, Peter A. Merkel, Robert Spiera, John C. Davis, E. William St. Clair, Joseph McCune, Steven R. Ytterberg, Nancy B. Allen, John H. Stone. (2005) Herpes zoster in immunocompromised patients: Incidence, timing, and risk factors. The American Journal of Medicine 118:12, 1416.e9-1416.e18
503
Heather F. Gidding, Marc Brisson, C. Raina Macintyre, Margaret A. Burgess. (2005) Modelling the impact of vaccination on the epidemiology of varicella zoster virus in Australia. Australian and New Zealand Journal of Public Health 29:6, 544-551
504
Vincent W. Bramwell, Yvonne Perrie. (2005) The rational design of vaccines. Drug Discovery Today 10:22, 1527-1534
505
KK Macartney, P Beutels, P McIntyre, MA Burgess. (2005) Varicella vaccination in Australia. Journal of Paediatrics and Child Health 41:11, 544-552
506
K Grimwood. (2005) Another vaccine, another step forward?. Journal of Paediatrics and Child Health 41:11, 541-542
507
R. G. Pebody. (2005) Universal varicella-zoster vaccination: is Europe ready?. International Journal of Clinical Practice 59:11, 1248-1250
508
Israel Steiner. (2005) Can vaccinating older adults against varicella zoster virus prevent herpes zoster and postherpetic neuralgia?. Nature Clinical Practice Neurology 1:1, 18-19
509
Susan S Chiu, Yu-Lung Lau. (2005) Review of the Varilrix™ varicella vaccine. Expert Review of Vaccines 4:5, 629-643
510
(2005) A Vaccine to Prevent Herpes Zoster. New England Journal of Medicine 353:13, 1414-1415
Free Full Text511
B. Schneeweiß. (2005) Kinderimpfung gegen Varizellen. Monatsschrift Kinderheilkunde 153:9, 838-844
512
Michael Houghton, Sergio Abrignani. (2005) Prospects for a vaccine against the hepatitis C virus. Nature 436:7053, 961-966
513
James C. Johnston. (2005) LIABILITY OF THE EXPERT NEUROLOGIST. Neurology Today 5:8, 4
514
P D Griffiths. (2005) A shot in the arm for immunotherapy. Reviews in Medical Virology 15:4, 215-217
515
Gilden , Donald H. , . (2005) Varicella–Zoster Virus Vaccine — Grown-ups Need It, Too. New England Journal of Medicine 352:22, 2344-2346
Full Text516
Arvin , Ann , . (2005) Aging, Immunity, and the Varicella–Zoster Virus. New England Journal of Medicine 352:22, 2266-2267
Full Text517
Antonio Volpi, Gerd Gross, Jana Hercogova, Robert W Johnson. (2005) Current Management of Herpes Zoster. American Journal of Clinical Dermatology 6:5, 317-325
518
Arturo Casadevall, Liise-anne Pirofski. (2005) Prospects of vaccines for medically important fungi Feasibility and prospects for a vaccine to prevent cryptococcosis. Medical Mycology 43:8, 667-680
519
Marta Feldmesser. (2005) Prospects of vaccines for medically important fungi. Medical Mycology 43:7, 571-587
- Letters
